

 SPRINGER PUBLISHING

THE APRN AND PA'S COMPLETE GUIDE TO

PRESCRIBING DRUG THERAPY 2022



MARI J. WIRFS



The APRN and PA's Complete Guide to Prescribing Drug Therapy

2022

Mari J. Wirfs, PhD, MN, RN, APRN, ANP-BC, FNP-BC, CNE, began her career with an ASN (1968, Dekalb College), and subsequently completed a BSN (1970, Georgia State University), MS (1975, Emory University), Post-Masters Certificates in Primary Care of the Adult (1997) and Family (1997, LSU Health Sciences Center), and PhD in Higher Education Administration and Leadership (1991, University of New Orleans). She is a nationally certified Adult Nurse Practitioner (1997, American Nurses Credentialing Center), Family Nurse Practitioner (1998, American Academy of Nurse Practitioners), and Certified Nurse Educator (2008, National League for Nursing). Her career spans 50+ years inclusive of collegiate undergraduate and graduate nursing education and clinical practice in critical care, pediatrics, psychiatric-mental health nursing, and advanced practice primary care nursing. During her academic career, she has achieved the rank of professor with tenure in two university systems.

Dr. Wirfs was a founding member of the medical staff in the establishment of Baptist Community Health Services, a community-based nonprofit primary care clinic founded post-hurricane Katrina in the New Orleans Lower Ninth Ward. Since 2002, Dr. Wirfs has served as clinical director and primary care provider at the Family Health Care Clinic, serving faculty, staff, students, and their families at New Orleans Baptist Theological Seminary (NOBTS). She is also adjunct graduate faculty, teaching neuropsychology and psychopharmacology, in the NOBTS Guidance and Counseling program. She is a long-time member of the National Organization of Nurse Practitioner Faculties (NONPF), Sigma Theta Tau International Honor Society of Nursing, and several other academic honor societies.

Dr. Wirfs has completed, published, and presented six quantitative research studies focusing on academic leadership, nursing education, and clinical practice issues, including one for the Army Medical Department conducted during her 8 year reserve service in the US Army Nurse Corps. Her publications include co-authored family primary care certification review books and study materials. Her first prescribing guide, *Clinical Guide to Pharmacotherapeutics for the Primary Care Provider*, was published by Advanced Practice Education Associates (APEA) from 1999 to 2014. *The APRN's Complete Guide to Prescribing Drug Therapy* (launched in 2016), *The APRN's Complete Guide to Prescribing Pediatric Drug Therapy* (launched in 2017), and *The PA's Complete Guide to Prescribing Drug Therapy* (launched in 2017) are published by Springer Publishing Company.

The APRN's Complete Guide to Prescribing Pediatric Drug Therapy 2018 was awarded second place, **Book of the Year 2017** in the Child Health Category, by the *American Journal of Nursing (AJN)*, official publication of the American Nurses Association (ANA). The panel of judges included the co-founder of the nurse practitioner role and first nurse practitioner program, Dr. Loretta C. Ford, Professor Emerita. Dr. Wirfs was the recipient of the 2018 AANP Nurse Practitioner State Award for Excellence from Louisiana by the American Association of Nurse Practitioners (AANP).



The APRN and PA's Complete Guide to Prescribing Drug Therapy

2022

*Mari J. Wirfs, PhD, MN, RN,
APRN, ANP-BC, FNP-BC, CNE*



SPRINGER PUBLISHING

Copyright © 2022 Springer Publishing Company, LLC

All rights reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Springer Publishing Company, LLC, or authorization through payment of the appropriate fees to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-646-8600, info@copyright.com or on the Web at www.copyright.com.

Springer Publishing Company, LLC
11 West 42nd Street
New York, NY 10036
www.springerpub.com

Acquisitions Editor: Rachel X. Landes

Composition: Exeter Premedia Services Private Ltd.

ISBN: 978-0-8261-8551-8

e-book ISBN: 978-0-8261-8549-5

DOI: 10.1891/9780826185495

21 22 23 24 / 5 4 3 2 1

This book is a quick reference for healthcare providers practicing in primary care settings. The information has been extrapolated from a variety of professional sources and is presented in condensed and summary form. It is not intended to replace or substitute for complete and current manufacturer prescribing information, current research, or knowledge and experience of the user. For complete prescribing information, including toxicities, drug interactions, contraindications, and precautions, the reader is directed to the manufacturer's package insert and the published literature. The inclusion of a particular brand name neither implies nor suggests that the author or publisher advises or recommends the use of that particular product or considers it superior to similar products available by other brand names. Neither the author nor the publisher makes any warranty, expressed or implied, with respect to the information, including any errors or omissions, herein.

Library of Congress Cataloging-in-Publication Data

Names: Wirfs, Mari J., author.

Title: The APRN and PA's complete guide to prescribing drug therapy 2020 / Mari J.

Wirfs.

Description: New York, NY: Springer Publishing Company, LLC, [2020] |

Includes bibliographical references and index.

Identifiers: LCCN 2017008900 | ISBN 9780826179333 | ISBN 9780826179340 (ebook)

Subjects: | MESH: Drug Therapy—nursing | Advanced Practice Nursing—methods

| Handbooks

Classification: LCC RM301 | NLM WY 49 | DDC 615.1—dc23

LC record available at <https://lcn.loc.gov/2017008900>

Contact us to receive discount rates on bulk purchases.

We can also customize our books to meet your needs.

For more information please contact: sales@springerpub.com

Publisher's Note: New and used products purchased from third-party sellers are not guaranteed for quality, authenticity, or access to any included digital components.

Printed in the United States of America.



CONTENTS

Reviewers	xxiii
Preface	xxv
Acknowledgments	xxvii
Quick Check Prescribing Reminders	xxviii

SECTION I: DRUG THERAPY BY CLINICAL DIAGNOSIS

3-Day Fever (Roseola Infantum)	646
Acetaminophen Overdose	3
Acne Rosacea	3
Acne Vulgaris	5
Acromegaly	9
Actinic Keratosis (AK)	11
Acute Bacterial Skins and Skin Structure Infection (ABSSSI)	142
Acute Exacerbation of Chronic Bronchitis (AECB)	74
Acute Urinary Tract Infection (UTI)	749
Adrenocortical Insufficiency	12
Agammaglobulinemia, Congenital or X-linked (see Immunodeficiency: Primary, Humoral, PHI)	392
Alcohol Dependence	13
Alcohol Withdrawal Syndrome	13
Allergic Reaction: General	14
Allergic Rhinitis	637
Allergic Sinusitis	637
Allergies: Multi-Food	15
Allergy: Peanut (<i>Arachis hypogaea</i>)	547
Alpha-1 Antitrypsin (AAT) Deficiency	15
Alzheimer's Disease	16
Amebiasis	18
Amebic Dysentery (see Amebiasis)	18
Amebic Liver Abscess	19
Amenorrhea: Secondary	19
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig Disease)	19
Anaphylaxis	20
Anemia: Beta Thalassemia-Associated	21
Anemia of Chronic Kidney Disease (CKD)	22
Anemia of Chronic Renal Failure (CRF)	22
Anemia: Folic Acid Deficiency	24
Anemia: Iron Deficiency	24
Anemia: Megaloblastic/Pernicious	25
Anemia: Pernicious	25
Anesthesia: Procedural Sedation	25
Angina Pectoris: Stable	26
Angioedema, Hereditary (HAE)	326
Ankylosing Spondylitis	499
Anorexia/Cachexia	29
Anthrax (<i>Bacillus anthracis</i>)	30

vi ■ Contents

Anxiety Disorder: Generalized (GAD)	32
Anxiety Disorder: Social (SAD)	32
Aphasia, Expressive: Stroke-induced	37
Aphthous Stomatitis (Mouth Ulcer, Canker Sore)	38
Arterial Insufficiency	557
Arthritis: Gouty	285
Ascariasis	470
Aphthous Stomatitis (Mouth Ulcer, Canker Sore)	38
Aspergillosis (<i>Scedosporium apiospermum</i> , <i>Fusarium</i> spp.)	39
Asthma	40
Asthma-COPD Overlap Syndrome (ACOS)	50
Asthma: Severe, Eosinophilia	51
Athlete's Foot	697
Atonic Bladder	374
Atrophic Vaginitis	54
Attention Deficit Hyperactivity Disorder (ADHD)	55
Atypical Hemolytic Uremic Syndrome (aHUS)	310
Bacterial Endocarditis: Prophylaxis	60
Bacterial Vaginosis (BV, <i>Gardnerella Vaginalis</i>)	62
Baldness: Male Pattern	63
Bartonella Infection (Cat Scratch Fever)	140
Basal Cell Carcinoma (BCC)	85
Bell's Palsy	64
Benign Essential Tremor	64
Benign Prostatic Hyperplasia (BPH)	64
Bile Acid Deficiency	65
Binge Eating Disorder	65
Bipolar Disorder	66
Bite: Cat	70
Bite: Dog	71
Bite: Human	72
Bladder Cancer	86
Blastomycosis	39
Blepharitis	73
Blepharoconjunctivitis: Bacterial	165
Blepharoptosis, Acquired (Droopy Eyelid)	73
Bloating (<i>see</i> Flatulence)	263
Boil (<i>see</i> Skin Infection: Bacterial)	664
<i>Bordetella</i> (Pertussis)	558
Bowel Resection With Primary Anastomosis	74
Breast Abscess (<i>see</i> Mastitis)	442
Breast Cancer	87
Bronchiolitis	74
Bronchitis: Acute (AECB, Acute Exacerbation of Chronic Bronchitis)	74
Bronchitis: Chronic (COPD, Chronic Obstructive Pulmonary Disease)	78
Bulimia Nervosa	84
Burn: Minor	84
Bursitis	85
C1 Esterase Inhibitor Deficiency	326
Cachexia	29
Calcium Deficiency	380
Callused Skin	663
Cancer: Basal Cell Carcinoma (BCC)	85

Cancer: Bladder, Urethral	86
Cancer: Breast	87
Cancer: Cutaneous Squamous Cell Carcinoma (CSCC)	97
Cancer: Cervical	96
Cancer: Colorectal	97
Cancer: Endometrial	97
Cancer: Epithelioid Sarcoma	98
Cancer: Esophageal	99
Cancer: Fallopian Tube	99
Cancer: Gastric	101
Cancer: Gastrointestinal Stromal Tumor	101
Cancer: Glioblastoma Multiforme	102
Cancer: Head and Neck Squamous Cell Carcinoma (HNSCC)	102
Cancer: Hepatocellular Carcinoma	103
Cancer: Leukemia	103
Cancer: Lung	106
Cancer: Lymphoma	111
Cancer: Melanoma	117
Cancer: Multiple Myeloma	118
Cancer: Ovarian	120
Cancer: Pancreatic	121
Cancer: Peritoneal	122
Cancer: Prostate	124
Cancer: Renal Cell Carcinoma (RCC)	127
Cancer: Squamous Cell Carcinoma (SCC)	129
Cancer: Thyroid	130
Cancer: Urothelial Carcinoma (UC)	131
Candidiasis: Abdomen, Bladder, Esophagus, Kidney	132
Candidiasis: Oral (Thrush)	133
Candidiasis: Skin	133
Candidiasis: Vulvovaginal (Moniliasis)	135
Canker Sore (<i>see</i> Aphthous Stomatitis)	38
Cannabinoid Hyperemesis Syndrome (CHS)	137
Carbuncle (<i>see</i> Skin Infection: Bacterial)	664
Carcinoid Syndrome Diarrhea (CSD)	139
Cardiomyopathy of Transthyretin-Mediated Amyloidosis	139
Carpal Tunnel Syndrome (CTS)	140
Cataplexy	470
Cat Bite	70
Cat Scratch Fever (<i>Bartonella</i> Infection)	140
Cellulite	141
Cellulitis	142
Cerumen Impaction	146
Cervical Cancer	96
Chagas Disease (<i>American Trypanosomiasis</i>)	147
Chalazion: Inflamed Meibomian Cyst, (<i>see</i> Stye)	674
Chancroid	148
Chemotherapy-Induced Nausea/Vomiting (CINV)	149
Chest Wall Syndrome (Costochondritis)	178
Chickenpox (Varicella)	152
<i>Chikungunya Virus</i>	153
Chikungunya-Related Arthritis	153
<i>Chlamydia trachomatis</i>	153

viii ■ Contents

Cholangitis, Primary Biliary (PBC)	155
Cholelithiasis	157
Cholera (<i>Vibrio cholerae</i>)	158
Chloasma	442
Christmas Disease	311
Chronic Idiopathic Constipation (CIC)	174
Chronic Kidney Disease (CKD)	22
Chronic Obstructive Pulmonary Disease (COPD)	78
Chronic Renal Failure (CRF)	22
<i>Clostridioides difficile</i>	161
<i>Clostridium tetani</i> (Tetanus)	668
Cluster Headache	294
Cluster Seizures	655
Cold Sore	332
Colic: Infantile	162
Colitis	602
Colon Cleanse	162
Colonoscopy Prep	162
Common Cold (URI, Viral Upper Respiratory Infection)	163
Community Acquired Pneumonia (CAP)	572
Complicated Intra-abdominal Infection (cIAI)	409
Complicated Urinary Tract Infection (cUTI)	746
<i>Condyloma Acuminata</i> (Venereal Wart)	766
Conjunctivitis: Allergic (Vernal)	170
Conjunctivitis/Blepharoconjunctivitis: Bacterial	165
Conjunctivitis: Chlamydial	169
Conjunctivitis: Fungal	169
Conjunctivitis: Gonococcal	170
Conjunctivitis: Viral	174
Constipation: Chronic Idiopathic (CIC)	174
Constipation: Occasional, Intermittent	175
Constipation: Opioid-induced (OIC)	492
COPD (<i>see</i> Bronchitis: Chronic or Emphysema)	78
Corneal Edema	178
Corneal Ulceration	178
Coronavirus (COVID-19)	178
COVID-19 (Coronavirus)	178
<i>Coxsackievirus</i> (Hand, Foot, and Mouth Disease)	292
Costochondritis (Chest Wall Syndrome)	178
Cradle Cap (<i>see</i> Dermatitis: Seborrheic)	212
Cramps: Abdominal, Intestinal	181
Crohn's Disease	182
Cryptosporidiosis (<i>Cryptosporidium parvum</i>)	186
<i>Cryptosporidium parvum</i> (Cryptosporidiosis)	186
Cushing's Syndrome	186
Cutaneous Larvae Migrants (Hookworm)	336
<i>Cyclospora cavetanensis</i> (Cyclosporiasis)	188
Cyclosporiasis (<i>Cyclospora cavetanensis</i>)	188
Cystic Fibrosis (CF)	189
Cystinuria	192
Cystitis (UTI, Urinary Tract Infection)	746
Cytomegalovirus (CMV, Retinitis)	626
Dandruff (<i>see</i> Dermatitis: Seborrheic)	212

Decubitus Ulcer	739	
Deep Vein Thrombosis (DVT) Prophylaxis	192	
Dehydration	192	
Delirium: End-of-Life	193	
Delirium Tremens	193	
Dementia	194	
Dengue Fever (<i>Dengue Virus</i>)	195	
Dental Abscess	196	
Dental Procedure Prophylaxis (see Bacterial Endocarditis: Prophylaxis)		60
Denture Irritation	197	
Depression, Major Depressive Disorder (MDD)	197	
Depression: Post-Partum	202	
Depression: Treatment Resistant (TRD)	203	
Dermatitis: Atopic (Eczema)	204	
Dermatitis: Contact	208	
Dermatitis: Diaper (see Diaper Rash)	220	
Dermatitis: Genus <i>Rhus</i> (Poison Oak, Poison Ivy, Poison Sumac)		210
Dermatitis: Seborrheic	212	
Diabetes Mellitus, Type 1 (T1DM)	714	
Diabetes Mellitus, Type 2 (T2DM)	722	
Diabetic Macular Edema	214	
Diabetic Neuropathic Pain	555	
Diabetic Peripheral Neuropathy (DPN)		216
Diabetic Retinopathy	214	
Diaper Rash	220	
Diarrhea: Acute	221	
Diarrhea: Carcinoid Syndrome (CSD)		222
Diarrhea: Chronic	222	
Diarrhea: Traveler's	223	
Digitalis Toxicity	225	
Diphtheria (<i>Corynebacterium diphtheriae</i>)		225
Distributive Shock	657	
Diverticulitis	226	
Diverticulosis	226	
Dog Bite	71	
Donovanosis (Granuloma Inguinale)		289
Dravet Syndrome	429	
Droopy Eyelid (Blepharoptosis, Acquired)		73
Dry Eye Syndrome (Keratoconjunctivitis [Sicca])		227
Dry Mouth Syndrome	663	
Duchenne Muscular Dystrophy (DMD)		228
Dust Mite Allergy	230	
Dysentery (see Amebiasis)	18	
Dysfunctional Uterine Bleeding (DUB)		231
Dyshidrosis	231	
Dyshidrotic Eczema (Dyshidrosis, Pompholyx)		231
Dyslipidemia (Hypercholesterolemia, Hyperlipidemia, Mixed Dyslipidemia)		231
Dysmenorrhea: Primary	237	
Dyspareunia (Post-menopausal Painful Intercourse)		238
Dyspepsia/Gastritis	266	
Eating Disorder: Anorexia Nervosa		65
Eating Disorder: Binge	65	
Eating Disorder: Bulimia Nervosa		84

x ■ Contents

Ebola Zaire Disease (<i>Zaire ebolavirus</i>)	239
Eczema (Atopic Dermatitis)	204
Edema	242
Emphysema	244
Encopresis	247
End-of-Life Delirium	193
Endometrial Cancer	97
Endometriosis	248
Enteritis	598
<i>Enterobius vermicularis</i> (see Pinworm)	565
Enuresis: Primary, Nocturnal	249
Eosinophilic Granulomatosis With Polyangiitis (formerly Churg-Strauss Syndrome)	250
Epicondylitis	251
Epididymitis	251
Epithelioid Sarcoma	98
Epstein-Barr Virus (EBV; see Mononucleosis)	454
Erectile Dysfunction (ED)	252
Erosive Esophagitis	254
Erysipelas	253
<i>Erythema Chronicum Migrans</i> (Lyme Disease)	436
<i>Erythema Infectiosum</i> (Fifth Disease)	263
Erythropoietic Protoporphyrria (EPP)	253
Esophageal Cancer	99
Esophagitis, Erosive	254
Exanthem Subitum (Roseola Infantum)	646
Exocrine Pancreas Insufficiency (EPI)	254
Extrapyramidal Side Effects (EPS)	256
Eye Pain	257
Eyelashes, Thin/Sparse (Hypotrichosis)	391
Facial Hair: Excessive/Unwanted	258
Fascioliasis (<i>Fasciola gigantica</i> , <i>Fasciola hepatica</i>)	431
Fecal Odor	258
Fever (Pyrexia)	258
Fever Blister	332
Fibrocystic Breast Disease	261
Fibromyalgia	261
Fifth Disease (<i>Erythema Infectiosum</i>)	263
Flatulence	263
Flu	400
Fluoridation, Water, <0.6 ppm	264
Folic Acid Deficiency (Anemia)	24
Folliculitis	264
Folliculitis Barbae	264
Foreign Body: Esophagus	266
Foreign Body: Eye	266
Furuncle	664
<i>Gardnerella Vaginalis</i> (BV, Bacterial Vaginosis)	62
Gastritis/Dyspepsia	266
Gastritis-Related Nausea/Vomiting	266
Gastroesophageal Reflux (GER)	267
Gastroesophageal Reflux Disease (GERD)	267
Gastrointestinal Stromal Tumor (GIST)	101
Gaucher Disease, Type 1	256

Generalized Anxiety Disorder (GAD)	32
Genital Herpes (<i>see</i> Herpes Genitalis, HSV Type II)	330
Genital Warts	765
German Measles (Rubella)	647
Giant Cell Arteritis (GCA)/Temporal Arteritis	274
Giardiasis (<i>Giardia lamblia</i>)	275
Gingivitis/Periodontitis	275
Glaucoma: Open Angle	276
Glioblastoma Multiform	102
Golfer's Elbow (<i>see</i> Epicondylitis)	251
Gonococcal Pharyngitis	559
Gonorrhea (<i>Neisseria gonorrhoeae</i>)	279
Gout	282
Gouty Arthritis	285
Graft Versus Host Disease (GVHD): Acute	287
Granulomatosis, Wegener's Granulomatosis	287
Granuloma Inguinale (Donovanosis)	289
Growth Failure	290
Growth Hormone Deficiency, Adult	291
Hair Loss (<i>see</i> Baldness: Male Pattern)	63
Hand, Foot, & Mouth Disease (<i>Coxsackievirus</i>)	292
Hansen's Disease	292
Headache: Cluster	294
Headache: Migraine	294
Headache: Tension (Muscle Contraction Headache)	302
Headache: Vascular	294
Head and Neck Squamous Cell Carcinoma (HNSCC)	102
Heartburn (<i>see</i> GER/GERD)	267
Heart Failure (HF)	304
<i>Helicobacter pylori</i> (<i>H. pylori</i>) Infection	309
Hemolytic Uremia Syndrome: Atypical (aHUS)	310
Hemophagocytic Lymphohistiocytosis (HLH)	311
Hemophilia A (Congenital Factor VIII Deficiency)	311
Hemophilia B	316
Hemorrhoids	316
Hepatic Porphyria, Acute (AHP)	318
Hepatitis A (HAV)	319
Hepatitis B (HBV)	320
Hepatitis C (HCV)	322
Hepatocellular Carcinoma	103
Hereditary Angioedema (HAE)	326
Herpangina	329
Herpes Facialis (HSV Type I)	332
Herpes Genitalis (HSV Type II)	330
Herpes Labialis (HSV Type I)	332
Herpes Simplex Virus Type I (HSV I, Herpes Facialis/Labialis)	332
Herpes Simplex Virus Type II (HSV II, Genital Herpes)	330
Herpes Zoster (HZ, Shingles)	332
Herpes Zoster Ophthalmicus (HZO)	334
Herpetic Dendritis	334
Hiccups: Intractable	335
Hidradenitis Suppurativa	335
Histoplasmosis	39

xii ■ Contents

Hives (Urticaria)	759
Hookworm (Uncinariasis, Cutaneous Larvae Migrans)	336
Hordeolum (<i>see</i> Stye)	674
Hospital-Acquired Bacterial Pneumonia (HABP)	567
Human Bite	72
Human Immunodeficiency Virus (HIV) Infection	337
Human Immunodeficiency Virus (HIV): Non-occupational Post-Exposure Prophylaxis (nPEP)	337
Human Immunodeficiency Virus (HIV): Occupational Post-Exposure Prophylaxis (oPEP)	337
Human Immunodeficiency Virus (HIV): Pre-Exposure Prophylaxis (PrEP)	337
Human Papillomavirus (HPV, Venereal Wart)	351
Huntington Disease-associated Chorea	352
Hypercalcemia	353
Hypercholesterolemia	231
Hyperemesis Gravidarum	353
Hyperhidrosis (Perspiration, Excessive)	354
Hyperhomocysteinemia	356
Hyperkalemia	356
Hyperlipidemia	231
Hyperparathyroidism (HPT)	358
Hyperphosphatemia	360
Hyperpigmentation	361
Hyperprolactinemia	362
Hypertension: Primary, Essential	362
Hyperthyroidism	378
Hypertriglyceridemia	378
Hyperuricemia	282
Hypoactive Sexual Desire Disorder (HSDD, Low Libido)	433
Hypocalcemia	380
Hypogonadism	684
Hypoglycemia: Acute	383
Hypokalemia	386
Hypomagnesemia	387
Hypoparathyroidism	388
Hypophosphatasia (Osteomalacia, Rickets)	389
Hypophosphatemia, X-Linked (XLH)	389
Hypopnea Syndrome	667
Hypotension: Neurogenic, Orthostatic	389
Hypotestosteronemia	684
Hypothyroidism	390
Hypotrichosis (Thin/Sparse Eyelashes)	391
Idiopathic Gastric Acid Hypersecretion (IGAH)	267
Idiopathic (Immune) Thrombocytopenia Purpura (ITP)	391
Idiopathic Peripheral Neuritis	417
Idiopathic Pulmonary Fibrosis (IPF)	618
Immunodeficiencies, Severe, Combined (<i>see</i> Immunodeficiency: Primary Humoral, PHI)	392
Immunodeficiency, Common Variable (<i>see</i> Immunodeficiency: Primary Humoral, PHI)	392
Immunodeficiency: Primary Humoral (PHI)	392
Impetigo Contagiosa (Indian Fire)	394
Impotence (<i>see</i> ED, Erectile Dysfunction)	252

Incontinence: Fecal	397
Incontinence: Urinary Overactive Bladder	397
Incontinence: Urinary Overflow, Atonic Bladder	397
Incontinence: Urinary Stress	397
Incontinence: Urinary Urge	397
Indian Fire (Impetigo Contagiosa)	394
Infectious Mononucleosis	454
Influenza, Seasonal (Flu)	400
Insect Bite/Sting	404
Insomnia	404
Intermittent Claudication (PAD, Peripheral Artery Disease)	557
Interstitial Cystitis	407
Intertrigo	409
Intra-abdominal Infection: Complicated (cIAI)	409
Iritis: Acute	411
Iron Deficiency (Anemia)	24
Iron Overload	412
Irritable Bowel Syndrome With Constipation (IBS-C)	413
Irritable Bowel Syndrome With Diarrhea (IBS-D)	414
Japanese Encephalitis Virus (JEV)	417
Jock Itch (Tinea Cruris)	695
Juvenile Idiopathic Arthritis (JIA)	417
Juvenile Rheumatoid Arthritis (JRA)	421
Keratitis	425
Keratitis: Allergic (Vernal)	426
Keratitis: Neurotrophic	425
Keratoconjunctivitis: Allergic (Vernal)	170
Keratitis/Keratoconjunctivitis: Herpes Simplex	425
Keratitis/Keratoconjunctivitis: Vernal	426
Keratoconjunctivitis (Sicca)	227
Kidney Stones	755
Labyrinthitis	426
Lactose Intolerance	426
Lambert-Eaton Myasthenic Syndrome (LEMS)	427
Larva Migrans: Cutaneous	427
Larva Migrans: Visceral	427
Lead Encephalopathy	427
Lead Poisoning	428
Lead Toxicity	428
Leg Cramps: Nocturnal, Recumbency	428
Leishmaniasis: Cutaneous	428
Leishmaniasis: Mucosal	428
Leishmaniasis: Visceral	428
Lennox-Gastaut Syndrome (LGS)	429
Lentigines: Benign, Senile	430
Leprosy	292
Leukemia, Acute Myeloid (AML)	103
Lice (<i>see</i> Pediculosis)	548
<i>Listeria monocytogenes</i> (Listeriosis)	431
Listeriosis (<i>Listeria monocytogenes</i>)	431
Liver Flukes	431
Lou Gehrig's Disease (ALS, Amyotrophic Lateral Sclerosis)	19
Low Back Strain (LBS)	433

xiv ■ Contents

Low Libido (see HSDD, Hypoactive Sexual Desire Disorder)	433
Lung Cancer	106
Lupus Nephritis	435
Lyme Disease (<i>Erythema Chronicum Migrans</i>)	436
Lymphadenitis	436
Lymphogranuloma Venereum	437
Macular Edema	214
Macular Edema: Diabetic	214
Macular Degeneration	214
Magnesium Deficiency	387
Major Depressive Disorder (MDD)	197
Malaria (<i>Plasmodium falciparum</i> , <i>Plasmodium vivax</i>)	438
Mastitis (Breast Abscess)	442
Measles (Rubeola)	647
Megaloblastic Anemia (Vitamin B12 Deficiency)	25
Melanasia (Hyperpigmentation)	361
Melanoma	117
Melasma/Chloasma	442
Ménière's Disease	443
Meningitis (<i>Neisseria meningitidis</i>)	444
Menometrorrhagia: Irregular Heavy Menstrual Bleeding	445
Menopause	445
Menorrhagia: Heavy Cyclical Menstrual Bleeding	445
Mesothelioma	450
Metastatic High-Risk Castration-Sensitive Prostate Cancer (CSPC)	598
Methamphetamine-induced Psychosis	451
Migraine Headache	294
Mitral Valve Prolapse (MVP)	454
Moniliasis (Vulvovaginal Candidiasis)	135
Mononucleosis (Mono)	454
Motion Sickness	455
Mouth Ulcer (Aphthous Stomatitis)	38
Multi-food Allergies	15
Multiple Myeloma	118
Multiple Sclerosis (MS)	455
Mumps (Infectious Parotitis, <i>Paramyxovirus</i>)	462
Muscle Contraction Headache (Tension Headache)	302
Muscle Strain	463
Myasthenia Gravis (MG)	467
<i>Mycobacterium tuberculosis</i> (TB)	710
Mycoplasma Pneumonia	577
<i>Mycobacterium leprae</i>	292
Myelodysplastic Syndromes (MDS)	468
Myelofibrosis	469
Narcolepsy	470
Narcotic Dependence (see Opioid Dependence)	486
Nausea/Vomiting: Chemotherapy-Induced (CINV)	475
Nausea/Vomiting: Opioid-Induced	493
Nausea/Vomiting: Post-Anesthesia (PONV)	475
Nausea/Vomiting of Pregnancy	353
<i>Neisseria meningitidis</i> (Meningitis)	444
Nerve Agent Poisoning	476
Neurogenic Detrusor Overactivity (NDO)	476

Neurogenic, Hypotension	389	
Neuromyelitis Optica Spectrum Disorder (NMOSD)		478
Neuropathic Pain: Generalized	555	
Neuropathic Pain: Peripheral	555	
Neurotrophic Keratitis	425	
Neutropenia: Chemotherapy-Associated		478
Neutropenia: Febrile	478	
Neutropenia: Myelosuppression-Associated		478
Nicotine Withdrawal Syndrome	700	
Nocturnal Enuresis (Primary Enuresis)	249	
Nocturnal Polyuria	586	
Non-24 Sleep-Wake Disorder	480	
nPrEP (Non-Occupational HIV Pre-Exposure Prophylaxis)		337
Non-Hodgkin's Lymphoma (see Cancer: Lymphoma)		111
Obesity	481	
Obsessive-Compulsive Disorder (OCD)	483	
Obstructive Sleep Apnea (OSA)	667	
Ocular Hypertension	276	
Odor: Fecal	258	
Onychomycosis (Fungal Nail)	485	
<i>Ophthalmia Neonatorum</i> : Chlamydial	485	
<i>Ophthalmia Neonatorum</i> : Gonococcal	486	
Opioid Dependence	486	
Opioid-induced Constipation (OIC)	492	
Opioid-induced Nausea/Vomiting (OINV)	493	
Opioid Overdose	495	
Opioid Use Disorder (OUD)	486	
Opioid Withdrawal Syndrome	486	
Organ Transplant Rejection Prophylaxis (OTRP)		496
Orthostatic Hypotension	389	
Osgood-Schlatter Disease	499	
Osteoarthritis	499	
Osteomalacia (Hypophosphatasia, Rickets)	389	
Osteoporosis	504	
Osteoporosis Prophylaxis (see Osteoporosis)		504
Otitis Externa	511	
Otitis Media: Acute	513	
Otitis Media: Serous (SOM)	516	
Otitis Media With Effusion (OME)	516	
Ovarian Cancer	517	
Overactive Bladder	397	
Overdose: Opioid	495	
Overflow Urinary Incontinence	397	
Paget's Disease: Bone	518	
Pain	519	
Painful Intercourse (Post-menopausal Dyspareunia)		238
Pancreatic Enzyme Deficiency	254	
Pancreatic Enzyme Insufficiency	533	
Panic Disorder	535	
Parathyroid Hormone Deficiency	388	
Paroxysmal Nocturnal Hemoglobinuria (PNH)		546
Parkinson's Disease (PD)	539	
Paronychia (Periungual Abscess)	545	

xvi ■ Contents

Parotitis: Infectious (Mumps)	462	
Paroxysmal Nocturnal Hemoglobinuria (PNH)		546
Peanut Allergy (<i>Arachis hypogaea</i>)	547	
Pediculosis Humanus Capitis (Head Lice)		548
Pediculosis Phthirus (Pubic Lice)	548	
Pelvic Inflammatory Disease (PID)	550	
Pemphigus Foliaceus (PF)	551	
Pemphigus Vulgaris (PV)	551	
Peptic Ulcer Disease (PUD)	552	
Periodontitis	275	
Peripheral Artery Disease (PAD)	533	
Peripheral Neuritis: Diabetic	555	
Peripheral Neuritis: Idiopathic	555	
Peripheral Neuropathic Pain	555	
Peripheral Vascular Disease (PVD)	557	
Peritoneal Cancer	122	
Periungal Abscess (Paronychia)	545	
Perleche (Angular Stomatitis)	558	
Pernicious Anemia (Vitamin B12 Deficiency)		25
Perspiration: Excessive (Hyperhidrosis)	354	
Pertussis (Whooping Cough)	558	
Pharyngitis: Gonococcal	559	
Pharyngitis: Streptococcal (Strep Throat)		559
Phenylketonuria (PKU)	562	
Pheochromocytoma	563	
Phthirus (Pubic Lice)	548	
Pinworm (<i>Enterobius vermicularis</i>)		565
Pityriasis Alba	566	
Pityriasis Rosea	566	
Plague (<i>Yersinia pestis</i>)	567	
Plantar Wart (<i>Verruca plantaris</i>)		765
Plaque Psoriasis	603	
Pneumococcal Pneumonia	578	
<i>Pneumocystis jiroveci</i> (Pneumonia)	579	
Pneumonia: Bacterial, Hospital-Acquired (HABP)		567
Pneumonia: Bacterial, Ventilator-Associated (VABP)		569
Pneumonia: Chlamydial	572	
Pneumonia: Community Acquired (CAP)	572	
Pneumonia: Community Acquired Bacterial (CABP)		572
Pneumonia: Legionella	577	
Pneumonia: Mycoplasma	577	
Pneumonia: Pneumococcal	578	
Pneumonia: <i>Pneumocystis jirovecii</i>	579	
Poliomyelitis	580	
Polyangiitis	580	
Polyarticular Juvenile Idiopathic Arthritis (PJIA)	417	
Polycystic Kidney Disease, Autosomal Dominant (ADPKD)		581
Polycystic Ovarian Syndrome (PCOS, Stein-Leventhal Disease)		582
Polycythemia Vera	582	
Polymyalgia Rheumatica	582	
Polyneuropathy, Chronic Inflammatory Demyelinating (CIDP)		583
Polyps: Nasal	584	
Polyuria: Nocturnal	586	

Pomphylx (Dyshidrosis, Dyshidrotic Eczema)	231
Post-Anesthesia Nausea/Vomiting	475
Post-Herpetic Neuralgia (PHN)	587
Post-menopausal Dyspareunia	238
Post-Partum Depression	202
Post-Traumatic Stress Disorder (PTSD)	591
Potassium Deficiency	386
Potassium Excess	356
Precocious Puberty, Central (CPP)	594
Pregnancy	596
Premenstrual Dysphoric Disorder (PMDD)	596
PrEP (HIV Pre-Exposure Prophylaxis)	337
Pressure Sore (Decubitus Ulcer)	739
Primary Biliary Cholangitis (PBC)	155
Primary Humoral Immunodeficiency (PHI)	392
Proctitis: Acute	598
Proctocolitis, Enteritis	598
Prostate Cancer	598
Prostatitis: Acute	598
Prostatitis: Chronic	599
Pruritus	599
Pruritus Ani (see Pruritus, see Hemorrhoids)	599
Pseudobulbar Affect (PBA) Disorder	601
Pseudogout	601
Pseudomembranous Colitis	602
Pseudorubella (Roseola Infantum)	646
Psittacosis	602
Psoriasis	603
Psoriatic Arthritis	610
Puberty: Central Precocious (CPP)	594
Pulmonary Arterial Hypertension (PAH, WHO Group I)	615
Pulmonary Fibrosis, Idiopathic (IPF)	618
Pyelonephritis: Acute	620
Pyelonephritis: Acute, Complicated (aCP)	621
Pyrexia (Fever)	258
Rabies (<i>Lyssavirus</i>)	623
Red Measles (Rubeola, 3-Day Measles)	647
Renal Calculi	755
Renal Cell Carcinoma	127
Respiratory Syncytial Virus (RSV)	625
Restless Legs Syndrome (RLS)	625
Retinitis: Cytomegalovirus (CMV)	626
Rheumatoid Arthritis (RA)	627
Rhinitis/Sinusitis: Allergic	637
Rhinitis Medicamentosa	642
Rhinitis: Vasomotor	644
Rhinosinusitis: Acute Bacterial (ABRS)	661
Rhinosinusitis: Chronic, with Nasal Polyps (CRSwNP)	642
Ricketts (Hypophosphatasia, Osteomalacia)	389
<i>Rickettsia rickettsii</i> (Rocky Mountain Spotted Fever)	645
Ringworm	694
River Blindness (Onchocerciasis)	645
Rocky Mountain Spotted Fever (RMSF, <i>Rickettsia rickettsii</i>)	645

xviii ■ Contents

Rosacea (Acne Rosacea)	3	
Roseola Infantum (Exanthem Subitum, Sixth Disease)		646
Rotavirus Gastroenteritis	646	
Roundworm (<i>Ascariasis</i>)	647	
Rubella (German Measles)	647	
Rubeola (Red Measles)	648	
<i>Salmonella typhi</i> (Typhoid Fever)		737
Salmonellosis	649	
<i>Sarcoptes scabiei</i> (Scabies)	649	
Scabies (<i>Sarcoptes scabiei</i>)	649	
Scarlatina (Scarlet Fever)	650	
Scarlet Fever (Scarlatina)	650	
Schistosomiasis	651	
Schizoaffective Disorder	652	
Schizophrenia	652	
Schizophrenia With Co-morbid Personality Disorder		652
Sebaceous Cyst: Infected (<i>see</i> Skin Infection)		664
Seborrhea (<i>see</i> Seborrheic Dermatitis)	212	
Seizure, Cluster	655	
Seizure Disorder	656	
Septic Shock	657	
Serous Otitis Media (SOM)	516	
Sexual Assault (STD/STI/VD Exposure)		656
Shift Work Sleep Disorder (SWSD)	668	
Shigellosis (Genus <i>Shigella</i>)	657	
Shingles (Herpes Zoster)	332	
Shock: Septic, Distributive	657	
Sickle Cell Disease (SCD)	658	
Sinusitis/Rhinosinusitis: Acute Bacterial (ABRS)		661
Sinusitis: Allergic	637	
Sixth Disease (<i>see</i> Roseola Infantum)		646
Sjögren-Larsson-Syndrome (SLS)	663	
Skin: Callused	663	
Skin Infection: Bacterial (Carbuncle, Folliculitis, Furuncle)		664
Sleep Apnea: Obstructive (Hypopnea Syndrome)	667	
Sleepiness: Excessive Shift Work Sleep Disorder (SWSD)		668
Sleep-Wake Disorder: Non-24	480	
Smallpox (<i>Variola Major</i>)	668	
Solar Keratosis (Actinic Keratosis)	11	
Spinal Muscular Atrophy (SMA)	669	
Sprain	671	
Squamous Cell Carcinoma (SCC)	129	
Status Asthmaticus	671	
Status Epilepticus	672	
STD/STI/VD Exposure, Sexual Assault		656
Stein-Leventhal Disease (PCOS, Polycystic Ovarian Syndrome)		582
Stomatitis: Angular (Perleche)	558	
Stomatitis (Aphthous Stomatitis)	38	
Stress Urinary Incontinence	397	
Stroke-induced Expressive Aphasia	37	
<i>Strongyloides stercoralis</i> (Threadworm)		688
Stye (Hordeolum)	674	
Sunburn	674	
Swimmer's Ear (Otitis Externa)		511

Syphilis (<i>Treponema pallidum</i>)	674	
Systemic Juvenile Idiopathic Arthritis (SJIA)		417
Systemic Lupus Erythematosus (SLE)	676	
Takayasu Arteritis	680	
Tapeworm (Cestode)	680	
Tardive Dyskinesia	681	
Temporal Arteritis	274	
Temporomandibular Joint (TMJ) Disorder		681
Tenosynovial Giant Cell Tumor (TGCT)		683
Tennis Elbow (<i>see</i> Epicondylitis)	251	
Tension Headache	302	
Testosterone Deficiency	684	
Tetanus (<i>Clostridium tetani</i>)	688	
Threadworm (<i>Strongyloides stercoralis</i>)	688	
Thrombocytopenia Purpura, Idiopathic (Immune) (ITP)		689
Thrombocytopenia Purpura, Thrombotic, Acquired Autoimmune (aTTP)		691
Thrush (Oral Candidiasis)	133	
Thyroid Cancer	692	
Thyroid Eye Disease	693	
Thyroid Hormone Deficiency	388	
Thyroid Hormone Excess	378	
Tic Douloureux (Trigeminal Neuralgia)		708
Tinea Capitis	693	
Tinea Corporis	694	
Tinea Cruris (Jock Itch)	695	
Tinea Pedis (Athlete's Foot)	697	
Tinea Versicolor	699	
Tobacco Cessation Syndrome	700	
Tobacco Dependence	700	
Tonsillitis: Acute	702	
Toxoplasmosis	704	
Travelers' Diarrhea	223	
Treatment Resistant Depression (TRD)	203	
Tremor: Benign Essential	63	
Trichinosis (<i>Trichinella spiralis</i>)	705	
Trichomoniasis (<i>Trichomonas vaginalis</i>)		706
Trichotillomania	707	
Trichuriasis (Whipworm)	767	
Trigeminal Neuralgia (Tic Douloureux)		708
Tuberculosis (TB): Pulmonary (<i>Mycobacterium tuberculosis</i>)		710
Tuberculosis (TB): Treatment-Resistant		710
Type 1 Diabetes Mellitus (T1DM)	714	
Type 2 Diabetes Mellitus (T2DM)	722	
Typhoid Fever (<i>Salmonella typhi</i>)	737	
Ulcer: Diabetic, Lower Extremity	738	
Ulcer: Decubitus/Pressure	739	
Ulcer: Neuropathic (Lower Extremity)	738	
Ulcer: Pressure/Decubitus	739	
Ulcer: Venous Insufficiency (Lower Extremity)		738
Ulcerative Colitis (UC)	739	
Uncinariasis (Hookworm, Cutaneous Larvae Migrans)		336
Upper Respiratory Infection (URI, Common Cold)		163
Urethral Cancer	86	
Urethritis: Nongonococcal (NGU)	745	

xx ■ Contents

Urge Urinary Incontinence	397	
Urinary Overflow Incontinence	397	
Urinary Retention: Unobstructive	746	
Urinary Stress Incontinence	397	
Urinary Tract Infection, Complicated (cUTI)	746	
Urinary Tract Infection (UTI, Acute Cystitis)	749	
Urinary Urge Incontinence	397	
Urolithiasis (Renal Calculi, Kidney Stones)	755	
Urothelial Carcinoma	131	
Urticaria: Acute (Hives)	759	
Urticaria: Mild, Chronic Idiopathic (CIU)	759	
Uncinariasis (Hookworm, Cutaneous Larvae Migrants)	336	
Upper Respiratory Infection (URI)	163	
Uterine Fibroids	762	
Uveitis: Posterior, Chronic, Non-Infectious	763	
Vaginal Irritation: External	763	
Varicella (Chickenpox)	152	
Varicose Veins	763	
<i>Variola Major</i> (Smallpox)	668	
Vascular Headache (Migraine Headache)	294	
Vasomotor Rhinitis	644	
Venereal Wart	765	
Venous Insufficiency Ulcer: Lower Extremity	738	
Ventilator-Associated Bacterial (VABP) Pneumonia	569	
<i>Verruca plantaris</i> (Plantar Wart)	765	
<i>Verruca vulgaris</i> (Common Wart)	765	
Vertigo	764	
<i>Vibrio cholera</i> (Cholera)	158	
Vitamin B12 Deficiency	25	
Vitiligo	764	
Vomiting	149	
von Willebrand Disease	311	
Wagener's Granulomatosis	287	
Wart: Common (<i>Verruca vulgaris</i>)	765	
Wart: Plantar (<i>Verruca plantaris</i>)	765	
Wart: Venereal, Human Papillomavirus (HPV), Condyloma Acuminata	766	
West Nile Virus (WNV)	767	
Whipworm (Trichuriasis)	767	
Whooping Cough (Pertussis)	558	
Wilson's Disease	768	
Wiskott-Aldrich Syndrome (<i>see</i> Immunodeficiency: Primary, Humoral [PHI])	392	
Wound: Infected, Non-surgical, Minor	770	
Wrinkles: Facial	772	
Xerosis	774	
Yellow Fever	774	
<i>Yersinia pestis</i> (Plague)	567	
<i>Zaire ebolavirus</i> (Ebola Zaire Disease)	239	
Zika Syndrome, Congenital (CZS)	775	
Zika Virus/Congenital Zika Syndrome (CZS)	775	
Zollinger-Ellison Syndrome	775	

SECTION II: APPENDICES

Appendix A. U.S. FDA Pregnancy Categories	779
Appendix B. U.S. Schedule of Controlled Substances	779

*Appendix C. Blood Pressure Guidelines	
*Appendix C.1. Blood Pressure Classifications (≥18 Years)	
*Appendix C.2. Blood Pressure Classifications (<18 Years)	
*Appendix C.3. Identifiable Causes of Hypertension (JNC-8)	
*Appendix C.4. CVD Risk Factors (JNC-8)	
*Appendix C.5. Diagnostic Workup of Hypertension (JNC-8)	
*Appendix C.6. Recommendations for Measuring Blood Pressure (JNC-8)	
*Appendix C.7. Patient-Specific Factors to Consider When Selecting Drug Treatment for Hypertension (JNC-8 and ASH)	
*Appendix C.8. Blood Pressure Treatment Recommendations (JNC-8)	
*Appendix D. Target Lipid Recommendations (ATP-IV)	
*Appendix D.1. Target TC, TG, HDL-C, Non-HDL-C (ATP-IV)	
*Appendix D.2. Target LDL-C (ATP-IV)	
*Appendix D.3. Non-HDL-C (ATP-IV)	
*Appendix E. Effects of Selected Drugs on Insulin Activity	
*Appendix F. Glycosylated Hemoglobin (HbA1c) and Average Blood Glucose Equivalent	
*Appendix G. Routine Immunization Recommendations	
*Appendix G.1. Administration of Vaccines	
*Appendix G.2. Contraindications to Vaccines	
*Appendix G.3. Route of Administration and Dose of Vaccines	
*Appendix G.4. Adverse Reactions to Vaccines	
*Appendix G.5. Minimum Interval Between Vaccine Doses	
Appendix G.6. Childhood (Birth-12 Years) Immunization Schedule	780
Appendix G.7. Childhood (Birth-12 Years) Immunization Catch-up Schedule	781
Appendix G.8. Recommended Adult Immunization Schedule	781
Appendix H. Contraceptives	782
Appendix H.1. Non-Hormonal Vaginal Contraceptives	782
Appendix H.2. Hormonal Contraceptive Contraindications and Recommendations	782
Appendix H.3. 28-Day Oral Contraceptives With Estrogen and Progesterone Content	783
Appendix H.4. Extended-Cycle Oral Contraceptives	790
Appendix H.5. Progesterone-Only Oral Contraceptives ("Mini-Pill")	790
*Appendix H.6. Injectable Contraceptives	
*Appendix H.6.1 Injectable Progesterone	
Appendix H.7. Transdermal Contraceptives	791
Appendix H.8. Contraceptive Vaginal Rings	791
Appendix H.9. Subdermal Contraceptives	792
Appendix H.10. Intrauterine Contraceptives	792
Appendix H.11. Emergency Contraception	792
*Appendix I: Anesthetic Agents for Local Infiltration and Dermal/Mucosal Membrane Application	
*Appendix J: NSAIDs	
Appendix K. Topical Corticosteroids by Potency	793
Appendix L. Oral Corticosteroids	796
Appendix M. Parenteral Corticosteroids	796
Appendix N. Inhalational Corticosteroids	797
Appendix O. Antiarrhythmia Drugs	799
Appendix P. Antineoplasia Drugs	801
Appendix Q. Antipsychosis Drugs	811
Appendix R. Anticonvulsant Drugs	813
Appendix S. Anti-HIV Drugs	815
Appendix T. Anticoagulants	818
Appendix T.1. Coumadin Titration and Dose Forms	818

xxii ■ Contents

Appendix T.2. Coumadin Over-Anticoagulation Reversal	819
Appendix T.3. Agents that Inhibit Coumadin's Anticoagulation Effects	819
Appendix U. Low Molecular Weight Heparins	819
Appendix V. Factor XA Inhibitors	819
Appendix W. Direct Thrombin Inhibitors	821
Appendix X. Platelet Aggregation Inhibitors	822
Appendix Y. Protease-Activated Receptor-1 (PAR-1) Inhibitors	823
*Appendix Z: Prescription Prenatal Vitamins	
*Appendix AA: Drugs for the Management of Allergy, Cough, and Cold Symptoms	
Appendix BB. Systemic Anti-infectives	823
Appendix CC. Antibiotic Dosing by Weight for Liquid Forms	832
Appendix CC.1. <i>acyclovir</i> (Zovirax Suspension)	832
Appendix CC.2. <i>amantadine</i> (Symmetrel Syrup)	832
Appendix CC.3. <i>amoxicillin</i> (Amoxil Suspension, Trimox Suspension)	833
Appendix CC.4. <i>amoxicillin+clavulanate</i> (Augmentin Suspension)	833
Appendix CC.5. <i>amoxicillin+clavulanate</i> (Augmentin ES 600 Suspension)	834
Appendix CC.6. <i>ampicillin</i> (Omnipen Suspension, Principen Suspension)	834
Appendix CC.7. <i>azithromycin</i> (Zithromax Suspension, Zmax Suspension)	835
Appendix CC.8. <i>cefaclor</i> (Ceclor Suspension)	835
Appendix CC.9. <i>cefadroxil</i> (Duricef Suspension)	836
Appendix CC.10. <i>cefdinir</i> (Omnicef Suspension)	836
Appendix CC.11. <i>cefixime</i> (Suprax Oral Suspension)	837
Appendix CC.12. <i>cefprozime proxetil</i> (Vantin Suspension)	837
Appendix CC.13. <i>cefprozil</i> (Cefzil Suspension)	837
Appendix CC.14. <i>ceftibuten</i> (Cedax Suspension)	838
Appendix CC.15. <i>cephalexin</i> (Keflex Suspension)	838
Appendix CC.16. <i>clarithromycin</i> (Biaxin Suspension)	839
Appendix CC.17. <i>clindamycin</i> (Cleocin Pediatric Granules)	839
Appendix CC.18. <i>dicloxacillin</i> (Dynapen Suspension)	840
Appendix CC.19. <i>doxycycline</i> (Vibramycin Syrup/Suspension)	840
Appendix CC.20. <i>erythromycin estolate</i> (Ilosone Suspension)	841
Appendix CC.21. <i>erythromycin ethylsuccinate</i> (E.E.S. Suspension, Ery-Ped Drops/Suspension)	841
Appendix CC.22. <i>erythromycin+sulfamethoxazole</i> (Eryzole, Pediazole)	842
Appendix CC.23. <i>fluconazole</i> (Diflucan Suspension)	842
Appendix CC.24. <i>furazolidone</i> (Furoxone Liquid)	843
Appendix CC.25. <i>griseofulvin, microsize</i> (Grifulvin V Suspension)	843
Appendix CC.26. <i>itraconazole</i> (Sporanox Solution)	843
Appendix CC.27. <i>loracarbef</i> (Lorabid Suspension)	843
Appendix CC.28. <i>nitrofurantoin</i> (Furadantin Suspension)	844
Appendix CC.29. <i>penicillin v potassium</i> (Pen-Vee K Solution, Veetids Solution)	844
Appendix CC.30. <i>rimantadine</i> (Flumadine Syrup)	845
Appendix CC.31. <i>tetracycline</i> (Sumycin Suspension)	845
Appendix CC.32. <i>trimethoprim</i> (Primsol Suspension)	845
Appendix CC.33. <i>trimethoprim+sulfamethoxazole</i> (Bactrim Suspension, Septra Suspension)	846
Appendix CC.34. <i>vancomycin</i> (Vancocin Suspension)	846
<i>Resources</i>	847
<i>Index: Brand/Generic Drug Name Cross-Reference With FDA Pregnancy Category and Controlled Drug Category</i>	857
<i>Key to Abbreviations</i>	Inside Back Cover



REVIEWERS

Kelley M. Anderson, PhD, FNP

Assistant Professor of Nursing, Georgetown University School of Nursing and Health Studies, Washington, DC

Kathleen Bradbury-Golas, DNP, RN, FNP-C, ACNS-BC

Associate Clinical Professor, Drexel University, Philadelphia, Pennsylvania; Family Nurse Practitioner, Virtua Medical Group, Hammonton and Linwood, New Jersey

Lori Brien, MS, ACNP-BC

Instructor, Advanced Practice Nursing Department, Georgetown University School of Nursing and Health Studies, Washington, DC

Jill Cash, MSN, APN, CNP

Nurse Practitioner, Logan Primary Care, West Frankfort, Illinois

Catherine M. Concert, DNP, RN, FNP-BC, AOCNP, NE-BC, CNL, CGRN

Nurse Practitioner-Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center; Clinical Assistant Professor, Pace University Lienhard School of Nursing, New York, New York

Kate DeMutis, MSN, CRNP

Senior Lecturer, Adult-Gerontology Primary Care Nurse Practitioner Program, Centralized Clinical Site Coordinator-Primary Care, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania

Gaye M. Douglas, DNP, MEd, APRN-BC

Assistant Professor of Nursing, Francis Marion University, Florence, South Carolina

Brenda Douglass, DNP, APRN, FNP-C, CDE, CTTS

Coordinator of Clinical Faculty, Assistant Clinical Professor, Drexel University College of Nursing and Health Professions, Philadelphia, Pennsylvania

Aileen Fitzpatrick, DNP, RN, FNP-BC

Clinical Assistant Professor, Pace University Lienhard School of Nursing, New York, New York

Nancy M. George, PhD, RN, FNP-BC, FAANP

Director of DNP Program, Associate Clinical Professor, Wayne State University College of Nursing, Detroit, Michigan

Tracy P. George, DNP, APRN-BC, CNE

Assistant Professor of Nursing, Amy V. Cockcroft Fellow 2016-2017, Francis Marion University, Florence, South Carolina

Cheryl Glass, MSN, WHNP, RN-BC

Clinical Research Specialist, KePRO, TennCare's Medical Solutions Unit, Nashville, Tennessee

Kathleen Gray, DNP, FNP-C

Assistant Professor, Georgetown School of Nursing and Health Studies, Washington, DC

Norma Stephens Hannigan, DNP, MPH, FNP-BC, DCC, FAANP

Clinical Professor of Nursing, Coordinator, Accelerated Second Degree (A2D) Program/ Sophomore Honors Program, Hunter College, CUNY Hunter-Bellevue School of Nursing, New York, New York

xxiv ■ Reviewers

Ella T. Heitzler, PhD, WHNP, FNP, RNC-OB

Assistant Professor, Georgetown University School of Nursing and Health Studies,
Washington, DC

Mary T. Hickey, EdD, RN

Clinical Professor of Nursing, Hunter College, CUNY Hunter-Bellevue School of Nursing,
New York, New York

Deborah L. Hopla, DNP, APRN-BC

Assistant Professor of Nursing, Director MSN/FNP Track, Amy V. Cockcroft Fellow, Francis
Marion University, Florence, South Carolina

Julia M. Hucks, MN, APRN-BC

Assistant Professor of Nursing, Family Nurse Practitioner, Francis Marion University,
Florence, South Carolina

Honey M. Jones, DNP, ACNP-BC

Acute Care Nurse Practitioner, Duke University Medical Center; Clinical Associate Faculty,
MSN Program, Duke University School of Nursing, Durham, North Carolina

Melissa H. King, DNP, FNP-BC, ENP-BC

Director of Advanced Practice Providers, Director of TelEmergency, Department of
Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi

Brittany M. Newberry, PhD, MSN, MPH, APRN, ENP, FNP

Board Certified Emergency and Family Nurse Practitioner; Vice President Education and
Professional Development of Hospital MD; Chair, Practice Committee of American Academy
of Emergency Nurse Practitioners; Adjunct Faculty, Emory University School of Nursing,
Atlanta, Georgia

Andrea Rutherford, MS, MPH, FNP-BC

Clinical Faculty Advisor, Adjunct Instructor, FNP Program, Georgetown University School of
Nursing and Health Studies, Washington, DC

Samantha Venable, MSN, RN, FNP

Family Nurse Practitioner, Correctional Nursing, Trabuco Canyon, California

Michael Watson, DNP, APRN, FNP-BC

Lead Family Nurse Practitioner, Wadley Regional Medical Center, Emergency Department,
Texarkana, Texas



The APRN and PA's Complete Guide to Prescribing Drug Therapy 2022 is a prescribing reference intended for use by healthcare providers in all clinical practice settings who are involved in the primary care management of patients with acute, episodic, and chronic health problems and needs for health promotion and disease prevention. It is organized in a concise and easy-to-read format. Comments are interspersed throughout, including such clinically useful information as laboratory values to be monitored, patient teaching points, and safety information. If pediatric indications for a drug have not been established or a drug is not recommended for a pediatric subgroup, this information is noted accordingly.

This reference is divided into two major sections. **Section I** presents drug treatment regimens for over 600 clinical diagnoses. Each drug is listed alphabetically by generic name, followed by: FDA pregnancy category (A, B, C, D, X); over-the-counter availability (OTC); DEA schedule (I, II, III, IV, V); generic availability (G); dosing regimens; brand/trade name(s); dose forms; whether tablets, caplets, or chew tabs are single scored (*), cross-scored (**), or tri-scored (***); flavors of chewable, sublingual, buccal, and liquid forms; and information regarding additives (i.e., dye-free, sugar-free, preservative-free or preservative type, alcohol-free or alcohol content). Non-pharmaceutical products and drugs that received initial FDA approval on or after June 30, 2015, do not have an FDA pregnancy letter designation. For information regarding special populations, including pregnant and breastfeeding females, refer to the manufacturer's package insert or visit <https://www.accessdata.fda.gov/scripts/cder/daf/> to view the product label online. Visit <https://www.drugs.com/pregnancy-categories.html> to view the FDA Pregnancy and Lactation Labeling Final Rule (PLLR) and new label format.

Section II presents clinically useful information organized in table format, including: the JNC-8 and ASH recommendations for hypertension management, childhood immunization recommendations, brand/trade name drugs (with contents) for the management of common respiratory symptoms, anti-infectives by classification, pediatric dosing by weight for liquid forms, glucocorticosteroids by potency and route of administration, and contraceptives by route of administration and estrogen and/or progesterone content. An alphabetical cross-reference index of drugs by generic and brand/trade name, with FDA pregnancy category and controlled drug schedule, facilitates quick identification of drugs by alternate names and page location(s).

Selected diseases and diagnoses (e.g., angina, ADHD, growth failure, glaucoma, Parkinson's disease, multiple sclerosis, cystic fibrosis) and selected drugs (e.g., antineoplastics, antipsychotics, antiarrhythmics, anti-HIV drugs, anticoagulants) are included because patients are frequently referred to primary care providers by specialists for follow-up monitoring and on-going management. Further, the shifting healthcare paradigm is such that with expanding roles and patient empowerment through education, initial diagnosis and initiation of treatment is increasing in primary care with measurable increases in access to quality healthcare and improved patient self-care. Several diseases are included that may not be prevalent in North America but have been identified in other parts of the world. Endemic diseases for which there is no FDA-approved drug treatment are also included with known transmission and treatment interventions. Accordingly, this guide serves primary care providers internationally. Today's healthcare providers are in an era of rapidly expanding knowledge in the field of genomics, and thus, each new edition of this prescribing guide contains new drug classes and new FDA-approved drugs.

For quick reference to pediatric weight-based dosing of a drug, the user is directed to the dose-by-weight table for that drug in the appendices. Potential safe, efficacious, prescribing and monitoring of drug therapy regimens requires adequate knowledge about (a) the pharmacodynamics and pharmacokinetics of drugs, (b) concomitant therapies, and (c) individual characteristics of the patient (e.g., age, weight, current and past medical history, physical examination findings, hepatic and renal function, and co-morbidities, and risk factors). Users of this clinical guide are encouraged to utilize the manufacturer's package insert, recommendations and guidance of specialists, standard-of-practice protocols, and the

current research literature for more comprehensive information about specific drugs (e.g., special precautions, drug-drug and drug-food interactions, risk versus benefit, age-related considerations, potential adverse reactions, and appropriate patient-centered care.



ACKNOWLEDGMENTS

This publication, which we consider to be a “must have” for students, academicians, and practicing clinicians represents the culmination of Springer Publishing Company’s collaborative team effort. The production team at Exeter Premedia Services, on behalf of Springer Publishing Company, managed the complex files as content was updated and cross-referenced for the final product. The work of reviewers from academia and clinical practice was essential to the process, and their contributions are greatly appreciated. I am proud of my association with these dedicated professionals, and I thank them on behalf of the healthcare community worldwide for supporting the end goal of quality healthcare for all people.

Sincerely, Dr. Mari J. Wirfs



ACE-Is and ARBs are contraindicated in the 2nd and 3rd trimesters of pregnancy. Addition of a daily ACE-I or ARB is strongly recommended for renal protection in patients with hypertension and/or diabetes. The “ACE inhibitor cough,” a dry cough, is an adverse side effect produced by an accumulation of bradykinins that occurs in 5% to 10% of the population and resolves within days of discontinuing the drug.

Alcohol is contraindicated with concomitant **narcotic analgesics, benzodiazepines, SSRIs, antihistamines, TCAs,** and other sedating agents due to risk of over-sedation.

Alpha-1 blockers have a potential adverse side effect of sudden hypotension, especially with first dose. Alert the patient regarding this “first-dose effect” and recommend the patient sit or lie down to take the first dose. Usually start at lowest dose and titrate upward.

Antidepressant monotherapy should be avoided until any presence of (hypo) mania or positive family history for bipolar spectrum disorder has been ruled out as antidepressant monotherapy can induce mania in the bipolar patient.

For patients 65 years-of-age and older, consult the **May 2017 Beers Criteria** for Potentially Inappropriate Medication (PIM) Use in Older Adults, to help improve the safety of prescribing medications for older adults, presented in table format at:
<https://www.priorityhealth.com/provider/clinical-resources/medication-resources/~media/documents/pharmacy/cms-high-risk-medications.pdf>

Aspirin is contraindicated in children and adolescents with *Varicella* or other viral illness, and 3rd trimester of pregnancy.

Beta-blockers, by all routes of administration, are generally contraindicated in severe COPD, history of or current bronchial asthma, sinus bradycardia, and 2nd or 3rd degree AV block. Use a cardio-specific beta blocker where appropriate in these cases.

A **biosimilar** product is one that has been FDA-approved based on data demonstrating that it is highly similar to a previously FDA-approved biological product, known as the reference product. Accordingly, the FDA has determined that there are no clinically meaningful differences between the biosimilar product and the reference product (e.g., **Cyltezo [adalimumab-adbm]** is biosimilar to **Humira [adalimumab]**). A biosimilar product has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its full prescribing information in the manufacturer’s package insert.

The **FDA Breakthrough Therapy Designation (BTD)** is intended to expedite the development and review of a drug candidate that is planned for use, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy Designation include the same benefits as Fast Track Designation (FTD), plus an organizational commitment involving the FDA’s senior managers with more intensive guidance from the FDA (e.g., **Zulresso [brexanolone]**) received the FDA Breakthrough Therapy Designation for treatment of post-partum depression.

Calcium channel blockers may cause the adverse side effect of pedal edema (feet, ankles, lower legs) that resolves with discontinuation of the drug.

Codeine is known to be excreted in breast milk: <12 years, not recommended; 12-<18, use extreme caution; not recommended for children and adolescents with asthma or other chronic breathing problem. The FDA and the European Medicines Agency (EMA) are investigating the safety of using *codeine*-containing medications to treat pain, cough, and colds in children 12-<18 years because of the potential for serious side effects, including slowed or difficult breathing.

Check **drug interactions** at https://www.drugs.com/drug_interactions.php

Check FDA **drug recalls, market withdrawals, and safety alerts** (<http://www.fda.gov/Safety/Recalls/default.htm>).

Contraceptives that are estrogen-progesterone combinations and **progesterone-only** are contraindicated in pregnancy (pregnancy category X).

Corticosteroids increase blood sugar in patients with diabetes and decrease immunity; therefore, consider risk versus benefit in susceptible patients, use lowest effective dose, and taper gradually to discontinue.

Diclofenac is contraindicated with *aspirin* allergy and, as with all other NSAIDs, should be avoided in late pregnancy (≥ 30 weeks) because it may cause premature closure of the ductus arteriosus.

Erythromycin may increase INR with concomitant warfarin, as well as increase serum level of digoxin, benzodiazepines, and statins.

Finasteride, a 5-alpha reductase inhibitor, is associated with low but increased risk of high-grade prostate cancer. Pregnant females should not touch broken tablets.

Fluoroquinolones and **quinolones** are contraindicated <18 years-of-age, pregnancy, and breastfeeding. *Exception:* in the case of anthrax, *ciprofloxacin* is indicated for patients <18 years-of-age and dosed based on mg/kg body weight. Risk of tendonitis or tendon rupture (ex: *ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin*).

Fluoroquinolones can increase the risk of aortic dissection or aortic aneurysm rupture and should not be used in patients at increased risk (including patients with peripheral artery disease, hypertension, Marfan syndrome, Ehlers-Danlos syndrome, and older adults) unless there is no other available treatment option.

The U.S. Preventive Services Task Force (USPSTF) recommends against using **hormone replacement therapy (HRT)** for primary prevention of chronic conditions among postmenopausal women. The harms associated with combined use of estrogen and a progestin, such as increased risks of invasive breast cancer, venous thromboembolism, and coronary heart disease, far outweigh the benefits.

Ibuprofen is contraindicated in children <6 months of age and in the 3rd trimester of pregnancy.

Live vaccines are contraindicated in patients who are immunosuppressed or receiving immunosuppressive therapy, including immunosuppressive levels of corticosteroid therapy.

Metronidazole and **tinidazole** are contraindicated in the 1st trimester of pregnancy. Alcohol

xxx ■ Quick Check Prescribing Reminders

is contraindicated during treatment with oral forms and for 72 hours after therapy due to a possible *disulfiram*-like reaction (nausea, vomiting, flushing, headache).

When prescribing **opioid analgesics**, presumptive urine **drug testing** (UDT) should be performed when opioid therapy for chronic pain is initiated, along with subsequent use as adherence monitoring, using in-office point of service testing to identify patients who are non-compliant or abusing prescription drugs or illicit drugs. American Society of Interventional Pain Physicians (ASIPP)

Orphan Drug designation means the drug is a first-in-class and/or the drug is for treatment of a rare disease and/or the drug is a first and only treatment for a disease and the application for FDA approval has received priority review as incentive to assist and encourage the development of drugs for rare diseases.

Oral **PDE5 inhibitors** are contraindicated in patients taking nitrates due to risk of hypotension or syncope (ex: *avanafil*, *sildenafil*, *tadalafil*, *varденаfil*).

Chronic long-term **proton pump inhibitor (PPI)** use carries a risk to renal function (consider risk-benefit and alternative treatment). PPIs should be discontinued, and should not be initiated, in patients with acute kidney injury (AKI) and chronic kidney disease (CKD).

Statins are strongly recommended as adjunctive therapy for patients with diabetes, with or without abnormal lipids.

Sulfonamides (ex: *sulfamethoxazole*, *trimethoprim*) are not recommended in pregnancy or lactation. CrCl 15-30 mL/min: reduce dose by 1/2; CrCl <15 mL/min: not recommended. Contraindicated with G6PD deficiency. A high fluid intake is indicated during sulfonamide therapy to avoid crystallization in the kidneys.

Tetracyclines are contraindicated in children <8 years-of-age, pregnancy, and breastfeeding (discolors developing tooth enamel). A side effect may be photo-sensitivity (photophobia). Do not take with antacids, calcium supplements, milk or other dairy, or within 2 hours of taking another drug (ex: *doxycycline*, *minocycline*).

Tramadol is known to be excreted in breast milk. The FDA and the European Medicines Agency (EMA) are investigating the safety of using *tramadol*-containing medications to treat pain in children 12-18 years because of the potential for serious side effects, including slowed or difficult breathing.

The **Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)** program is an FDA-required program designed to ensure informed risk-benefit decisions before initiating treatment, and while patients are treated to ensure appropriate use of TIRF medicines. The purpose of the TIRF REMS Access program is to mitigate the risk of misuse, abuse, addiction, overdose, and serious complications due to medication errors with the use of TIRF medicines. You must enroll in the TIRF REMS Access program to prescribe, dispense, or distribute TIRF medicines. To register, call the TIRF REMS Access program at 1-866-822-1483 or register online at <https://www.tirfremssaccess.com/TirfUI/remss/home.action>



**The APRN and PA's Complete Guide
to Prescribing Drug Therapy**

2022



SECTION I

DRUG THERAPY BY CLINICAL DIAGNOSIS



ACETAMINOPHEN OVERDOSE

ANTIDOTE/CHELATING AGENT

- ▶ **acetylcysteine (B)(G)** *Loading Dose:* 150 mg/kg administered over 15 minutes; *Maintenance:* 50 mg/kg administered over 4 hours; then 100 mg/kg administered over 16 hours

Pediatric: same as adult

Acetadote *Vial: soln for IV infusion after dilution:* 200 mg/ml (30 ml; dilute in D₅W (preservative-free)

Comment: **Acetaminophen** overdose is a medical emergency due to the risk of irreversible hepatic injury. An IV infusion of **acetylcysteine** should be started as soon as possible and within 24 hours if the exact time of ingestion is unknown. Use a serum **acetaminophen** nomogram to determine need for treatment. Extreme caution is needed if used with concomitant hepatotoxic drugs.



ACNE ROSACEA

Comment: All acne rosacea products should be applied sparingly to clean, dry skin as directed. Avoid use of topical corticosteroids.

- ▶ **ivermectin (C)(G)** apply bid

Soolantra *Crn:* 1% (30 gm)

Comment: **Soolantra** is a macrocyclic lactone. Exactly how it works to treat rosacea is unknown.

TOPICAL ALPHA-1A ADRENOCEPTOR AGONIST

- ▶ **oxymetazoline hcl (B)** apply a pea-sized amount once daily in a thin layer covering the entire face (forehead, nose, cheeks, and chin) avoiding the eyes and lips; wash hands immediately

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Rhofade *Crn* 1% (30 gm tube)

Comment: **Rhofade** acts as a vasoconstrictor. Use with caution in patients with cerebral or coronary insufficiency, Raynaud's phenomenon, thromboangiitis obliterans, scleroderma, or Sjögren's syndrome. **Rhofade** may increase the risk of angle closure glaucoma in patients with narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of potentiation of vascular insufficiency or acute angle closure glaucoma develop.

TOPICAL ALPHA-2 AGONIST

- ▶ **brimonidine (B)** apply to affected area once daily

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Mirvaso

Gel: 0.33% (30, 45 gm tube; 30 gm pump)

Comment: **Mirvaso** is indicated for persistent erythema; **brimonidine** constricts dilated facial blood vessels to reduce redness.

TOPICAL ANTIMICROBIALS

- ▶ **azelaic acid (B)(G)** apply to affected area bid
 - Azelex** *Crn:* 20% (30, 50 gm)
 - Finacea** *Gel:* 15% (30 gm); *Foam:* 15% (50 gm)

- ▶ **metronidazole (B)** apply to clean dry skin

MetroCream apply bid

Emol crm: 0.75% (45 gm)

MetroGel apply once daily

Gel: 1% (60 gm tube; 55 gm pump)

MetroLotion apply bid

Lotn: 0.75% (2 oz)

- ▶ **minocycline** topical foam apply to affected areas once daily; gently rub into the skin

Pediatric: <9 years: not recommended; ≥9 years: same as adult

Amzeeq Aerosol can: 4% (30 gm)

Comment: **Amzeeq (minocycline)** is a tetracycline-class drug indicated to treat inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients >9 years-of-age. The propellant in **Amzeeq** is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. Use of tetracycline-class of drugs orally during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent discoloration of the teeth (yellow-gray-brown) and reversible inhibition of bone growth. If *Clostridium difficile*-associated diarrhea occurs, discontinue **Amzeeq**. If liver injury is suspected, discontinue **Amzeeq**. Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Avoid co-administration with penicillins. **Amzeeq** may cause fetal harm when used during pregnancy. Breastfeeding is not recommended while using **Amzeeq**.

- ▶ **sodium sulfacetamide (C)(G)** apply 1-3 x daily

Klaron Lotn: 10% (2 oz)

- ▶ **sodium sulfacetamide+sulfur (C)**

Clenia Emollient Cream apply 1-3 x daily

Wash: sod sulfa 10%+sulfur 5% (10 oz)

Clenia Foaming Wash wash affected area once or twice daily

Wash: sod sulfa 10%+sulfur 5% (6, 12 oz)

Rosula Gel apply 1-3 x daily

Gel: sod sulfa 10%+sulfur 5% (45 ml)

Rosula Lotion apply tid

Lotn: sod sulfa 10%+sulfur 5% (45 ml) (alcohol-free)

Rosula Wash wash bid

Clnsr: sod sulfa 10%+sulfur 5% (335 ml)

ORAL ANTIMICROBIALS

- ▶ **doxycycline (D)(G)** 40-100 mg bid

Pediatric: <8 years: not recommended; ≥8 years, <100 lb: 2 mg/lb on first day in 2 divided doses, followed by 1 mg/lb/day in 1-2 divided doses; ≥8 years, ≥100 lb: same as adult; *see Appendix CC.19. doxycycline* (Vibramycin Syrup/Suspension) *for dose by weight*

Acticlate Tab: 75, 150**mg

Adoxa Tab: 50, 75, 100, 150 mg ent-coat

Doryx Tab: 50, 75, 100, 150, 200 mg del-rel

Doxteric Tab: 50 mg del-rel

Monodox Cap: 50, 75, 100 mg

Oracea Cap: 40 mg del-rel

Vibramycin Tab: 100 mg; **Cap:** 50, 100 mg; **Syr:** 50 mg/5 ml (raspberry-apple) (sulfites); **Oral susp:** 25 mg/5 ml (raspberry)

Vibra-Tab Tab: 100 mg film-coat

- ▶ **minocycline (D)(G)** 200 mg on first day; then 100 mg q 12 hours x 9 more days

Pediatric: <8 years: not recommended; ≥8 years, <100 lb: 2 mg/lb on first day in 2 divided doses, followed by 1 mg/lb q 12 hours x 9 more days; ≥8 years, ≥100 lb: same as adult

Dynacin Cap: 50, 100 mg

Minocin Cap: 50, 75, 100 mg; **Oral susp:** 50 mg/5 ml (60 ml) (custard) (sulfites, alcohol 5%)



ORAL CONTRACEPTIVES

see Appendix H. Contraceptives

see Appendix H.4. Progesterone-Only Oral Contraceptives (“Mini-Pill”)

Comment: In their 2016 published report, researchers concluded different hormonal contraceptives have significantly varied effects on acne. Women (n = 2,147) who were using a hormonal contraceptive at the time of their first consultation for acne comprised the study sample. Participants completed an assessment at baseline to report how the contraceptive affected their acne. Then the researchers used the Kruskal-Wallis test and logistic regression analysis to compare the outcomes by contraceptive type. On average, the vaginal ring and combined oral contraceptives (COCs) improved acne, whereas depot injections, subdermal implants, and hormonal intrauterine devices worsened acne. In the COC categories, *drospirenone* was the most helpful in improving acne, followed by *norgestimate* and *desogestrel*, and then *levonorgestrel* and *norethindrone*. Although triphasic progestin dosage had a positive effect on acne, estrogen dosage did not.

TOPICAL ANDROGEN RECEPTOR INHIBITOR

- ▶ *clascoterone* apply a thin layer to affected area twice daily (morning and evening)
Pediatric: <12 years: not recommended; ≥12 years: same as adult

Winlevi Crm: 1%

Comment: *Winlevi* is a first-in-class topical androgen receptor inhibitor for the treatment of acne vulgaris. Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with *clascoterone*. Attempt to withdraw use if HPA suppression occurs. Pediatric patients may be more susceptible to systemic toxicity. Elevated potassium level has been observed in some subjects during clinical trials. The most common adverse reactions (incidence 7-12%) have been erythema, reddening, pruritis, and scaling/dryness. Additionally, edema, stinging, and burning has occurred in >3% of patients and were reported in a similar percentage of patients treated with vehicle. There are no available data on *Winlevi* cream use in pregnant females to evaluate for an associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are no data regarding the presence of *clascoterone* or its metabolite in human milk or effects on the breastfed infant.

TOPICAL ANTIMICROBIALS

Comment: All topical antimicrobials should be applied sparingly to clean, dry skin.

- ▶ *azelaic acid* (B)(G) apply to affected area bid
Azelex Crm: 20% (30, 50 gm)
Finacea Gel: 15% (30 gm); *Foam:* 15% (50 gm)

- ▶ *benzoyl peroxide* (C)(G)

Comment: *Benzoyl peroxide* may discolor clothing and linens.

Benzac-W initially apply to affected area once daily; increase to bid-tid as tolerated

Gel: 2.5, 5, 10% (60 gm)

Benzac-W Wash wash affected area bid

Wash: 5% (4, 8 oz); 10% (8 oz)

Benzagel apply to affected area one or more x/day

Gel: 5, 10% (1.5, 3 oz) (alcohol 14%)

Benzagel Wash wash affected area bid

Gel: 10% (6 oz)

Desquam X⁵ wash affected area bid

Wash: 5% (5 oz)

Desquam X¹⁰ wash affected area bid

Wash: 10% (5 oz)

Triaz apply to affected area daily bid

Lotn: 3, 6, 9% (bottle), 3% (tube); *Pads:* 3, 6, 9% (jar)

ZoDerm apply once or twice daily

Gel: 4.5, 6.5, 8.5% (125 ml); *Crms:* 4.5, 6.5, 8.5% (125 ml); *Clnsr:* 4.5, 6.5, 8.5% (400 ml)

▶ **clindamycin topical (B)** apply to affected area bid

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Cleocin T Pad: 1% (60/pck; alcohol 50%); *Lotn:* 1% (60 ml); *Gel:* 1% (30, 60 gm); *Soln w. applicator:* 1% (30, 60 ml) (alcohol 50%)

Clindagel *Gel:* 1% (42, 77 gm)

Evoclin Foam: 1% (50, 100 gm) (alcohol)

▶ **clindamycin+benzoyl peroxide topical (C)** apply to affected area once daily

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Acanya (G) apply to affected area once daily-bid

Gel: clin 1.2%+benz 2.5% (50 gm)

BenzaClin (G) apply to affected area bid

Gel: clin 1%+benz 5% (25, 50 gm)

Duac apply daily in the evening

Gel: clin 1%+benz 5% (45 gm)

Onexon Gel (G) apply to affected area once daily

Gel: clin 1.2%+benz 3.75% (50 gm pump) (alcohol-free) (preservative-free)

▶ **dapsone topical (C)(G)** apply to affected area bid

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Aczone *Gel:* 5, 7.5% (30, 60, 90 gm pump)

▶ **erythromycin+benzoyl peroxide (C)** initially apply to affected area once daily; increase to bid as tolerated

Benzamycin Topical Gel *Gel:* eryth 3%+benz 5% (46.6 gm/jar)

▶ **minocycline topical foam** apply to affected areas once daily; gently rub into the skin

Pediatric: <9 years: not recommended; ≥9 years: same as adult

Amzeeq Aerosol can: 4% (30 gm)

Comment: **Amzeeq (minocycline)** is a tetracycline-class drug indicated to treat inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients >9 years-of-age. The propellant in **Amzeeq** is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. Use of tetracycline-class of drugs orally during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent discoloration of the teeth (yellow-gray-brown) and reversible inhibition of bone growth. If *Clostridioides difficile*-associated diarrhea occurs, discontinue **Amzeeq**. If liver injury is suspected, discontinue **Amzeeq**. Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Avoid co-administration with penicillins. **Amzeeq** may cause fetal harm when used during pregnancy. Breastfeeding is not recommended while using **Amzeeq**.

▶ **sodium sulfacetamide (C)(G)** apply tid

Klaron *Lotn:* 10% (2 oz)

ORAL ANTIMICROBIALS

▶ **doxycycline (D)(G)** 100 mg bid

Pediatric: <8 years: not recommended; ≥8 years, <100 lb: 2 mg/lb on first day in 2 divided doses, followed by 1 mg/lb/day in 1-2 divided doses; ≥8 years, ≥100 lb:

same as adult; *see Appendix CC.19. doxycycline* (Vibramycin Syrup/Suspension) for dose by weight

Acticlate Tab: 75, 150**mg

Adoxa Tab: 50, 75, 100, 150 mg ent-coat

Doryx Tab: 50, 75, 100, 150, 200 mg del-rel

Doxteric Tab: 50 mg del-rel

Monodox Cap: 50, 75, 100 mg

Oracea Cap: 40 mg del-rel

Vibramycin Tab: 100 mg; **Cap:** 50, 100 mg; **Syr:** 50 mg/5 ml (raspberry-apple) (sulfites); **Oral susp:** 25 mg/5 ml (raspberry)

Vibra-Tab Tab: 100 mg film coat

- ▶ **erythromycin base (B)(G)** 250 mg qid, 333 mg tid or 500 mg bid x 7-10 days; then taper to lowest effective dose

Pediatric: <45 kg: 30-50 mg in 2-4 divided doses x 7-10 days; ≥45 kg: same as adult

Ery-Tab Tab: 250, 333, 500 mg ent-coat

PCE Tab: 333, 500 mg

- ▶ **erythromycin ethylsuccinate (B)(G)** 400 mg qid x 7-10 days

Pediatric: 30-50 mg/kg/day in 4 divided doses x 7-10 days; may double dose with severe infection; max 100 mg/kg/day; *see Appendix CC.21. erythromycin ethylsuccinate* (E.E.S. Suspension, Ery-Ped Drops/Suspension) for dose by weight

EryPed Oral susp: 200 mg/5 ml (100, 200 ml) (fruit); 400 mg/5 ml (60, 100, 200 ml) (banana); **Oral drops:** 200, 400 mg/5 ml (50 ml) (fruit); **Chew tab:** 200 mg wafer (fruit)

E.E.S. Oral susp: 200, 400 mg/5 ml (100 ml) (fruit)

E.E.S. Granules Oral susp: 200 mg/5 ml (100, 200 ml) (cherry)

E.E.S. 400 Tablets Tab: 400 mg

- ▶ **minocycline (D)(G)** initially 50-200 mg/day in 2 divided doses; reduce dose to once daily after improvement

Pediatric: <8 years: not recommended; ≥8 years: same as adult

Dynacin Cap: 50, 100 mg

Minocin Cap: 50, 75, 100 mg; **Oral susp:** 50 mg/5 ml (60 ml) (custard) (sulfites, alcohol 5%)

Minolira Tab: 105, 135 mg ext-rel

Solodyn Tab: 55, 65, 80, 105, 115 mg ext-rel

Comment: Once-daily dosing of **Minolira** or **Solodyn**, extended-release **minocyclines**, is approved for inflammatory lesions of non-nodular moderate-to-severe acne vulgaris for patients ≥12 years-of-age. The recommended dose of **Solodyn** is 1 mg/kg once daily x 12 weeks.

- ▶ **sarecycline** one tab daily based with or without food; <9 years: not recommended; ≥9 years: 33-54 kg: 60 mg; 55-84 kg: 100 mg; 85-136 kg: 150 mg

Seysara Tab: 60, 100, 150 mg

Comment: **Seysara** is a first-in-class, **tetracycline**-derived, once daily treatment for inflammatory lesions of non-nodular moderate-to-severe acne. Efficacy of **Seysara** beyond 12 weeks and safety beyond 12 months have not been established. **Seysara** has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, **Seysara** should be used only as indicated. If *Clostridioides difficile*-associated diarrhea (antibiotic-associated colitis) occurs, discontinue **Seysara**. Central nervous system side effects, including light-headedness, dizziness, or vertigo, have been reported with **tetracycline** use. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery. These symptoms may disappear during therapy and may disappear when the drug is discontinued. **Seysara** may cause intracranial hypertension;

discontinue **Seysara** if symptoms occur. Photosensitivity can occur with **Seysara**; minimize or avoid exposure to natural or artificial sunlight. **tetracycline** is contraindicated <8 years-of-age, in pregnancy, and lactation (discolors developing tooth enamel). A side effect may be photo-sensitivity (photophobia). Avoid co-administration with retinoids and penicillin. Decrease anticoagulant dosage as appropriate. Monitor for toxicities of drugs that may require dosage reduction (e.g., P-glycoprotein substrates) and monitor for toxicities. Do not take with antacids, calcium supplements, iron preparations, milk or other dairy, or within two hours of taking another drug.

- ▶ **tetracycline (D)(G)** initially 1 gm/day in 2-4 divided doses; after improvement, 125-500 mg daily
Pediatric: <8 years: not recommended; ≥8 years, <100 lb: 25-50 mg/kg/day in 2-4 divided doses; ≥8 years, ≥100 lb: same as adult; see Appendix CC.31. **tetracycline (Sumycin Suspension) for dose by weight**
Achromycin V Cap: 250, 500 mg
Sumycin Tab: 250, 500 mg; **Cap:** 250, 500 mg; **Oral susp:** 125 mg/5 ml (100, 200 ml) (fruit) (sulfitcs)

TOPICAL RETINOIDs

Comment: Wash affected area with a soap-free cleanser; pat dry and wait 20 to 30 minutes; then apply sparingly to affected area; use only once daily in the evening. Avoid applying to eyes, ears, nostrils, and mouth.

- ▶ **adapalene (C)** apply once daily at HS
Pediatric: <12 years: not recommended; ≥12 years: same as adult
Differin Crm: 0.1% (45 gm); **Gel:** 0.1, 0.3% (45 gm) (alcohol-free); **Pad:** 0.1% (30/pck) (alcohol 30%); **Lotn:** 0.1% (2, 4 oz)
- ▶ **tazarotene (X)(G)** apply to affected area once daily at HS
Pediatric: <12 years: not recommended; ≥12 years: same as adult
Arazlo Tube: 0.045% (45 gm)
Comment: **Arazlo (tazarotene)** is a lotion formulation of retinoid **tazarotene** approved for the topical treatment of acne vulgaris in patients ≥9 years-of-age.
Avage Cream Crm: 0.1% (30 gm)
Tazorac Cream Crm: 0.05, 0.1% (15, 30, 60 gm)
Tazorac Gel Gel: 0.05, 0.1% (30, 100 gm)
- ▶ **retinoin (C)(G)** apply sparingly to affected area once or twice daily
Comment: Dryness, pain, erythema, irritation, and exfoliation may occur during treatment. Avoid paranasal creases and mucous membranes. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing when sun exposure cannot be avoided. Use with caution if allergic to fish due to potential for allergenicity to fish protein.
Pediatric: <12 years: not recommended; ≥12 years: same as adult
Altreno Lotn: 0.05% (45 gm tube)
Comment: **Altreno** is indicated for children >9 years-of-age. Apply a thin film to affected area bid.
Atralin Gel Gel: 0.05% (45 gm)
Avita Crm: 0.025% (20, 45 gm); **Gel:** 0.025% (20, 45 gm)
Retin-A Cream Crm: 0.025, 0.05, 0.1% (20, 45 gm)
Retin-A Gel Gel: 0.01, 0.025% (15, 45 gm) (alcohol 90%)
Retin-A Liquid Soln: 0.05% (alcohol 55%)
Retin-A Micro Gel Gel: 0.04, 0.08, 0.1% (20, 45 gm)
Tretin-X Cream Crm: 0.075% (35 gm) (parabens-free, alcohol-free, propylene glycol-free)
- ▶ **trifarotene 0.005% cream** apply a thin layer to the affected areas of the face chest, shoulders, and/or back once daily, in the evening, to clean and dry skin; avoid

contact with the eyes, lips, paranasal creases, and mucous membranes

Pediatric: <9 years: not recommended; ≥9 years: same as adult

Aklief Pump: 30, 45, 70 gm

TOPICAL RETINOID+ANTIMICROBIAL COMBINATIONS

Comment: Wash affected area with a soap-free cleanser; pat dry and wait 20-30 minutes; then apply sparingly to affected area; use only once daily in the evening. Avoid eyes, ears, nostrils, and mouth.

▶ **adapalene+benzoyl peroxide (C)(G)** apply a thin film once daily

Pediatric: <18 years: not recommended

Epiduo Gel: adap 0.1%+benz 2.5% (45 gm)

Epiduo Forte Gel Pump gel: adap 0.3%+benz 2.5% (15, 30, 45, 60 gm)

▶ **tretinoin+clindamycin (C)(G)** apply a thin film once daily

Pediatric: <18 years: not recommended

Ziana Gel: tret 0.025%+clin 1.2% (30, 60 gm)

ORAL RETINOID

Comment: Oral retinoids are indicated only for severe recalcitrant nodular acne unresponsive to conventional therapy including systemic antibiotics.

▶ **isotretinoin (X)** initially 0.5-1 mg/kg/day in 2 divided doses; maintenance 0.5-2 mg/kg/day in 2 divided doses x 4-5 months; repeat only if necessary 2 months following cessation of first treatment course

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Accutane Cap: 10, 20, 40 mg (parabens)

Amnesteem Cap: 10, 20, 40 mg (soy)

Comment: *Isotretinoin* is highly teratogenic and, therefore, female patients should be counseled prior to initiation of treatment as follows: Two negative pregnancy tests are required prior to initiation of treatment and monthly thereafter. Not for use in females who are or who may become pregnant or who are breastfeeding. Two effective methods of contraception should be used for 1 month prior to, during, and continuing for 1 month following completion of treatment. Low-dose *progestin* (mini-pill) may be an *inadequate* form of contraception. No refills; a new prescription is required every 30 days and prescriptions must be filled within 7 days. Serum lipids should be monitored until response is established (usually initially and again after 4 weeks). Bone growth, serum glucose, ESR, RBCs, WBCs, and liver enzymes should be monitored. Blood should not be donated during, or for 1 month after, completion of treatment. Avoid the sun and artificial UV light. *isotretinoin* should be discontinued if any of the following occurs: visual disturbances, tinnitus, hearing impairment, rectal bleeding, pancreatitis, hepatitis, significant decrease in CBC, hyperlipidemia (particularly hypertriglyceridemia).



ACROMEGALY

GROWTH HORMONE RECEPTOR ANTAGONIST

▶ **pegvisomant (B)** *Loading dose:* 40 mg SC; *Maintenance:* 10 mg SC daily; titrate by 5 mg (increments or decrements, based on IGF-1 levels) every 4 to 6 weeks; max 30 mg/day

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Somavert Inj: 10, 15, 20 mg

Comment: Prior to initiation of *pegvisomant*, patients should have baseline fasting serum glucose, HgbA1c, serum K⁺ and Mg⁺⁺, liver function tests (LFTs), EKG, and gall bladder ultrasound.

CYCLOHEXAPEPTIDE SOMATOSTATIN

- ▶ **pasireotide (C)** administer SC in the thigh or abdomen; initial dose is 0.6 mg or 0.9 mg bid; titrate dose based on response and tolerability; for patients with moderate hepatic impairment (*Child-Pugh Class B*), the recommended initial dosage is 0.3 mg twice daily and max dose 0.6 mg twice daily; avoid use in patients with severe hepatic impairment (*Child-Pugh Class C*)

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Signifor LAR Amp: 0.3, 0.6, 0.9 mg/ml, single-dose, long-act rel (LAR) susp for inj

SOMATOSTATIN ANALOG

- ▶ **octreotide acetate**

Comment: *octreotide acetate* is indicated for reduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) (somatomedin C) in adult patients with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Monitor patients treated with *octreotide acetate* for cholelithiasis. Glucose monitoring is recommended and antidiabetic treatment may need adjustment. Hypothyroidism may occur; monitor thyroid levels periodically. Bradycardia, arrhythmia, or conduction abnormalities may occur; use with caution in at-risk patients. Common adverse side effects may include diarrhea, cholelithiasis, abdominal pain, flatulence. Advise pre-menopausal females of the potential for an unintended pregnancy.

PARENTERAL FORMS

- ▶ **octreotide acetate**

Bynfezia Pen initiate at 50 mcg SC 3 x/day; typical dose is 100 mcg SC 3 x/day

Prefilled Pen: 2.5 mg/ml (2500 mcg/ml) 2.8 ml, single-patient-use

Sandostatin initiate at 50 mcg SC 3 x/ day; IGF-I (somatomedin C) levels every 2 weeks can be used to guide titration; goal is to achieve growth hormone levels <5 ng/mL or IGF-I (somatomedin C) levels <1.9 unit/mL (males) and <2.2 unit/mL (females); most common effective dose is 100 mcg SC 3 x/day; some patients require up to 500 mcg SC 3 x/day for maximum effectiveness; >300 mcg/day seldom results in additional biochemical benefit; if dose increase fails to provide additional benefit, the dose should be reduced; IGF-I (somatomedin C) or growth hormone levels should be re-evaluated at 6-month intervals

Vial: 200, 1000 mcg/5 ml, multidose; *Amp:* 50, 100, 500 mcg/ml

Comment: **Sandostatin** should be withdrawn yearly for approximately 4 weeks from patients who have received irradiation to assess disease activity. If growth hormone or IGF-I (somatomedin C) levels increase and signs and symptoms recur, **Sandostatin** therapy may be resumed.

Sandostatin LAR Depot after administering **Sandostatin** 50 mcg SC 3 x/day for 2 weeks, initiate **Sandostatin LAR Depot** suspension 20 mg IM intragluteally every 4 weeks for 3 months

Vial: 10, 20, 30 mg/6 ml, single-use

Comment: **Sandostatin LAR Depot** is indicated for treatment in patients with acromegaly who have first responded to **Sandostatin** with achievement of growth hormone levels <5 ng/mL or IGF-I (somatomedin C) levels <1.9 unit/mL (males) and <2.2 unit/mL (females).

ORAL FORM

- ▶ **Mycapssa** initiate at 40 mg daily, as 20 mg twice daily; titrate in increments of 20 mg; max 80 mg/day; monitor insulin-like growth factor 1 (IGF-1) levels and patient's signs and symptoms every two weeks during the dose titration or as indicated once the maintenance dose is achieved, monitor IGF-1 levels and

patient's signs and symptoms monthly or as indicated; *ESRD*: initiate at 20 mg once daily; titrate and adjust maintenance dose based on IGF-1 levels, signs and symptoms, and tolerability (take with a glass of water on an empty stomach, at least 1 hour before a meal or at least 2 hours after a meal)

Cap: 20 mg del-rel

Comment: *Mycapssa* is an oral form of *octreotide* indicated for long-term maintenance treatment of patients with acromegaly who have responded to and tolerated treatment with parental *octreotide* or *lanreotide*. Most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis. Concomitant use of *Mycapssa* with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., *quinidine*) should be used with caution.



ACTINIC KERATOSIS (AK)

- ▶ ***aminolevulinic acid* 10%** clean and prepare all lesions prior to applying gel 1 mm thick and include 5 mm of the surrounding skin; max application area 20 cm² and max 2 gm per treatment; apply an occlusive dressing x 3 hours; photodynamic therapy involves preparation of lesions, application of the **Ameluz**, occlusion, and illumination with BF-RhodoLED only by a qualified healthcare provider; remove remaining gel at the end of the treatment; may re-treat in 3 months after the initial treatment; BF-RhodoLED user manual for detailed lamp safety and operating instructions.

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Ameluz Gel: 10% (2 gm tube) 100 mg/gm of ***aminolevulinic acid hcl*** (equivalent to 78 mg/gm ***aminolevulinic acid***) (xanthan gum, soybean phosphatidylcholine, polysorbate 80, medium-chain triglycerides, dibasic sodium phosphate, monobasic sodium phosphate, propylene glycol, sodium benzoate, isopropyl alcohol)

Comment: **Ameluz (*aminolevulinic acid*) 10%** gel, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED lamp, is indicated for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The most common adverse reactions (incidence ≥10%) have been application site erythema, pain/burning, irritation, edema, pruritus, exfoliation, scab formation, induration, and vesicles. Concomitant use of other photosensitizing agents may increase the risk of phototoxic reaction to photodynamic therapy (e.g., St. John's wort, ***griseofulvin***, thiazide diuretics, sulfonyleureas, phenothiazines, sulfonamides, quinolones, and tetracyclines). Patient and healthcare provider must wear protective eyewear before and during operation of the BF-RhodoLED lamp. Treated lesions should be protected from sunlight exposure for 48 hours posttreatment. Special care should be taken to avoid bleeding during lesion preparation in patients with inherited or acquired a coagulation disorder. Avoid direct contact of **Ameluz** with the eyes and mucous membranes. There are no human or animal reproductive studies of **Ameluz** use in pregnancy to inform a drug-associated risk. Systemic absorption of ***aminolevulinic acid*** is negligible. No data are available regarding the presence of ***aminolevulinic acid*** in human milk or effects on the breastfed infant; however, breastfeeding is not expected to result in infant exposure to the drug due to negligible systemic absorption.

- ▶ ***diclofenac sodium* 3% (C; D ≥30 wks)(G)** apply to lesions bid x 60-90 days

Pediatric: <12 years: not established; ≥12 years: same as adult

Solaraze Gel Gel: 3% (50 gm) (benzyl alcohol)

12 ■ Actinic Keratosis (AK)

Comment: *Diclofenac* is contraindicated with *aspirin* allergy. As with other NSAIDs, *Solaraze Gel* should be avoided in late pregnancy (≥ 30 weeks) because it may cause premature closure of the ductus arteriosus.

Voltaren Gel apply qid; avoid non-intact skin

Gel: 1% (100 gm)

- ▶ **fluorouracil (X)(G)** apply to lesion(s) daily-bid until erosion occurs, usually 2-4 weeks

Pediatric: <12 years: not recommended; ≥ 12 years: same as adult

Carac Crm: 0.5% (30 gm)

Efudex (G) Crm: 5% (25 gm); *Soln:* 2, 5% (10 ml w. dropper)

Fluoroplex Crm: 1% (30 gm); *Soln:* 1% (30 ml w. dropper)

- ▶ **imiquimod (B)(G)**

Pediatric: <18 years: not recommended; ≥ 18 years: same as adult

Aldara (G) rub into lesions before bedtime and remove with soap and water 8 hours later; treat 2 times per week; max 16 weeks

Crm: 5% (single-use pkts/carton)

Zyclara rub into lesions before bedtime and remove with soap and water 8 hours later; treat for 2-week cycles separated by a 2-week no-treatment cycle; max 2 packs per application; max one treatment course per area

Crm: 3.75% (single-use pkts; 28/carton) (parabens)

- ▶ **ingenol mebutate (C)** limit application to one contiguous skin area of about 25 cm² using one unit dose tube; allow treated area to dry for 15 minutes; wash hands immediately after application; may remove with soapy water after 6 hours; *Face and Scalp:* apply 0.015% gel to lesions daily x 3 days; *Trunk and Extremities:* apply 0.05% gel to lesions daily x 2 days

Pediatric: <18 years: not recommended; ≥ 18 years: same as adult

Picato Gel: 0.015% (3 single-use tubes), 0.05% (2 single-use tubes)

Src KINASE AND TUBULIN POLYMERIZATION INHIBITOR

- ▶ **tirbanibulin** apply to the treatment field on the face or scalp once daily for 5 consecutive days using 1 single-dose packet per application

Pediatric: <18 years: not established; ≥ 18 years: same as adult

Klisyri Oint: 1%, single-dose pkts (25 mg/pkt)

Comment: *Klisyri (tirbanibulin)* is a first-in-class dual Src Kinase and tubulin polymerization inhibitor for the topical treatment of actinic keratosis on the face or scalp. The most common adverse reactions (incidence $\geq 2\%$) have been local skin reactions, application site pruritus, and application site pain.



ADRENOCORTICAL INSUFFICIENCY

CORTICOSTEROID

- ▶ **hydrocortisone granules** individualize the dose, using the lowest possible dosage; *Recommended Starting Replacement Dose:* 8 to 10 mg/m² daily (higher doses may be needed based on patient's age and symptoms of the disease; lower starting doses may be sufficient in patients with residual but decreased endogenous cortisol production; round the dose to the nearest 0.5 mg or 1 mg. More than one capsule may be needed to supply the required dose; divide the total daily dose into 3 doses and administer 3 times daily; older patients may have their daily dose divided by 2 and administered twice daily; do not swallow the capsule; do not chew or crush the granules; see the mfr pkg insert for full prescribing information and for detailed administration instructions.

Alkindi Sprinkle Cap: 0.5 mg, 1 mg, 2 mg, 5 mg oral granules

Comment: *Alkindi Sprinkle* is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency. Use the minimum dosage to achieve desired clinical response. Common adverse reactions

for corticosteroids include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite, and weight gain. Corticosteroids decrease bone formation and increase bone resorption, which may lead to inhibition of bone growth and development of osteoporosis. Use may be associated with severe psychiatric adverse reactions, such as euphoria, mania, psychosis with hallucinations, and delirium or depression. Symptoms typically emerge within a few days or weeks of starting the treatment. Most reactions resolve after either dose reduction or withdrawal. Cataracts, glaucoma, and central serous chorioretinopathy have been reported with prolonged use of high doses. Monitor patients for blurred vision or other visual disturbances. Prolonged use with supraphysiologic doses may cause Cushing's syndrome. Monitor patients for signs and symptoms of Cushing's syndrome every 6 months, pediatric patients under one year of age may require more frequent monitoring. Long-term use in excessive doses may cause growth retardation; monitor the patient's growth. Excessive doses may increase the risks of new infections or exacerbation of latent infections with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic infections. Monitor patients for signs and symptoms of infections. Treat all infections seriously and initiate stress dosing of corticosteroids early. Undertreatment or sudden discontinuation of therapy may lead to adrenocortical insufficiency, adrenal crisis, and death. Increase the dose during periods of stress. Switch patients who are vomiting, severely ill, or unable to take oral medications to parenteral corticosteroid formulations.



ALCOHOL DEPENDENCE, DETOXIFICATION/ALCOHOL WITHDRAWAL SYNDROME

ALCOHOL WITHDRAWAL SYNDROME

Comment: Total length of time of a given detoxification regimen and/or length of time of treatment at any dose reduction level may be extended based on patient-specific factors, including potential or actual seizure, hallucinosis, and increased sympathetic nervous system activity (severe anxiety, unwanted elevation in vital signs). If any of these symptoms are anticipated or occur, revert to an earlier step in the dosing regimen to stabilize the patient, extend the detoxification timeline, and consider appropriate adjunctive drug treatments (e.g., anticonvulsants, antipsychotic agents, antihypertensive agents, sedative hypnotics agents).

- ▼ **clorazepate (D)(IV)(G)** in the following dosage schedule: *Day 1:* 30 mg initially, followed by 30-60 mg in divided doses; *Day 2:* 45-90 mg in divided doses; *Day 3:* 22.5-45 mg in divided doses; *Day 4:* 15-30 mg in divided doses; Thereafter, gradually reduce the daily dose to 7.5-15 mg; then discontinue when patient's condition is stable; max dose 90 mg/day

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Tranxene Tab: 3.75, 7.5, 15 mg

Tranxene T-Tab Tab: 3.75*, 7.5*, 15*mg

- ▼ **chlordiazepoxide (D)(IV)(G)**

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Librium 50-100 mg q 6 hours x 24-72 hours; then q 8 hours x 24-72 hours; then q 12 hours x 24-72 hours; then daily x 24-72 hours

Cap: 5, 10, 25 mg

Librium Injectable 50-100 mg IM or IV; then 25-50 mg IM tid-qid prn; max 300 mg/day

Inj: 100 mg

- ▼ **diazepam (D)(IV)(G)** 2-10 mg q 6 hours x 24-72 hours; then q 8 hours x 24-72 hours; then q 12 hours x 24-72 hours; then daily x 24-72 hours

14 ■ Alcohol Dependence, Detoxification/Alcohol Withdrawal Syndrome

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Diastat Rectal gel delivery system: 2.5 mg

Diastat Acu Dial Rectal gel delivery system: 10, 20 mg

Valium Tab: 2*, 5*, 10*mg

Valium Injectable Vial: 5 mg/ml (10 ml); *Amp:* 5 mg/ml (2 ml); *Prefilled syringe:* 5 mg/ml (5 ml)

Valium Intensol Oral Solution Conc oral soln: 5 mg/ml (30 ml w. dropper) (alcohol 19%)

Valium Oral Solution Oral soln: 5 mg/5 ml (500 ml) (wintergreen-spice)

- ▶ **oxazepam (C)** 10-15 mg tid-qid x 24-72 hours; decrease dose and/or frequency every 24-72 hours; total length of therapy 5-14 days; max 120 mg/day

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Cap: 10, 15, 30 mg

ABSTINENCE THERAPY

GABA Taurine Analog

- ▶ **acamprosate (C)(G)** 666 mg tid; begin therapy during abstinence; continue during relapse; *CrCl 30-50-mL/min:* max 333 mg tid; *CrCl <30 mL/min:* contraindicated

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Campral Tab: 333 mg ext-rel

Comment: **Campral** does not eliminate or diminish alcohol withdrawal symptoms.

AVERSION THERAPY

- ▶ **disulfiram (X)(G)**

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Antabuse 500 mg once daily x 1-2 weeks; then 250 mg once daily

Tab: 250, 500 mg; *Chew tab:* 200, 500 mg

Comment: **Disulfiram** use requires informed consent. Contraindications: severe cardiac disease, psychosis, concomitant use of **isoniazid**, **phenytoin**, **paraldehyde**, and topical and systemic alcohol-containing products. Approximately 20% remains in the system for 1 week after discontinuation.



ALLERGIC REACTION: GENERAL

Oral Second Generation Antihistamines *see* Appendix AA. Drugs for the Management of Allergy, Cough, and Cold Symptoms online at <https://connect.springerpub.com/content/reference-book/978-0-8261-7935-7/back-matter/part02/back-matter/bmatter27>

Topical Corticosteroids *see* Appendix K. Topical Corticosteroids by Potency

Parenteral Corticosteroids *see* Appendix M. Parenteral Corticosteroids

Oral Corticosteroids *see* Appendix L. Oral Corticosteroids

FIRST GENERATION PARENTERAL ANTIHISTAMINE

- ▶ **diphenhydramine (C)(G)** 25-50 mg IM immediately; then q 6 hours prn
Pediatric: <12 years: *See mfr pkg insert:* 1.25 mg/kg up to 25 mg IM x 1 dose; then every 6 hours prn

Benadryl Injectable Vial: 50 mg/ml (1 ml single-use); 50 mg/ml (10 ml multi-dose); *Amp:* 10 mg/ml (1 ml); *Prefilled syringe:* 50 mg/ml (1 ml)

FIRST GENERATION ORAL ANTIHISTAMINES

- ▶ **diphenhydramine (B)(G)** 25-50 mg q 6-8 hours; max 100 mg/day
Pediatric: <2 years: not recommended; 2-6 years: 6.25 mg q 4-6 hours; max 37.5 mg/day; >6-12 years: 12.5-25 mg q 4-6 hours; max 150 mg/day; >12 years: same as adult

Benadryl (OTC) Chew tab: 12.5 mg (grape) (phenylalanine); **Liq:** 12.5 mg/5 ml (4, 8 oz); **Cap:** 25 mg; **Tab:** 25 mg; **Dye-free soft gel:** 25 mg; **Dye-free liq:** 12.5 mg/5 ml (4, 8 oz)

▶ **hydroxyzine (C)(G)** 50-100 mg qid; max 600 mg/day

Pediatric: <6 years: 50 mg/day divided qid; ≥6 years: 50-100 mg/day divided qid

Atarax Tab: 10, 25, 50, 100 mg; **Syr:** 10 mg/5 ml (alcohol 0.5%)

Vistaril Cap: 25, 50, 100 mg; **Oral susp:** 25 mg/5 ml (4 oz) (lemon)



ALLERGIES: MULTI-FOOD

Comment: Eight food-types cause about 90% of food allergy reactions—*Milk* (mostly in children), *Eggs*, *Peanuts*, *Tree nuts*, (e.g., walnuts, almonds, pine nuts, brazil nuts, and pecans), *Soy*, *Wheat* (and other grains with gluten, including barley, rye, and oats), *Fish* (mostly in adults), *Shellfish* (mostly in adults). Combining *omalizumab* with oral immunotherapy (OIT) significantly improves the effectiveness of OIT in children with multiple food allergies, according to the results of a recent study. Researchers conducted a blinded, phase 2 clinical trial including children aged 4 to 15 years who had multi-food allergies validated by double-blind, placebo-controlled food challenges. Participants were randomly assigned (3:1) to either receive *omalizumab* with multi-food oral immunotherapy or placebo. *omalizumab* and placebo were administered for 16 weeks, with oral immunotherapy beginning at 8 weeks. Overall, at week 36, a significantly greater proportion of the *omalizumab*-treated participants passed double-blind, placebo-controlled food challenges, compared with placebo (83% vs 33%). No serious or severe adverse events were reported. In multi-food allergic patients, *omalizumab* improves the efficacy of multi-food oral immunotherapy and enables safe and rapid desensitization.

IGE BLOCKER (IGG1K MONOCLONAL ANTIBODY)

▶ **omalizumab (B)** 150-375 mg SC every 2-4 weeks based on body weight and pre-treatment serum total IgE level; max 150 mg/injection site; approved for patient self-administration after education by a qualified healthcare provider

Pediatric: <12 years: not recommended; 30-90 kg + IgE >30-100 IU/ml 150 mg q 4 weeks; 90-150 kg + IgE >30-100 IU/ml or 30-90 kg + IgE >100-200 IU/ml or 30-60 kg + IgE >200-300 IU/ml 300 mg q 4 hours; >90-150 kg + IgE >100-200 IU/ml or >60-90 kg + IgE >200-300 IU/ml or 30-70 kg + IgE >300-400 IU/ml 225 mg q 2 weeks; >90-150 kg + IgE >200-300 IU/ml or >70-90 kg + IgE >300-400 IU/ml or 30-70 kg + IgE >400-500 IU/ml or 30-60 kg + IgE >500-600 IU/ml or 30-60 kg + IgE >600-700 IU/ml 375 mg q 2 weeks; ≥12 years: same as adult

Xolair Vial: 150 mg, single-dose, pwdr for SC injection after reconstitution
Prefilled syringe: 75 mg/0.5 ml, 150 mg/1 ml single-dose (preservative-free)



ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY

Comment: Alpha-1 antitrypsin (AAT, a major circulating serine protease inhibitor) deficiency is a common genetic (autosomal co-dominant) condition characterized by low serum levels of AAT. Absence of deficiency of AAT accelerates lung tissue degradation and increases the risk for development of COPD and early onset emphysema, particularly in smokers. Extrapulmonary complications of AAT deficiency include liver disease (onset as early as childhood), granulomatosis with polyangiitis (GPA, previously known as Wegener's granulomatosis), vasculitis, and necrotizing panniculitis. Management of symptomatic AAT and exacerbations includes bronchodilators (LABA/LAMA) and inhaled corticosteroids in line with the management of COPD symptoms and exacerbations (Global Initiative for Chronic Obstructive Lung Disease [GOLD]). Management of AAT includes smoking cessation; avoidance of environmental pollutants; immunizations against

influenza, pneumonia, and hepatitis; antibiotic therapy as needed (with *amoxicillin* or a macrolide); and management in a critical care setting for acute respiratory distress/failure. Pharmacologic management of AAT deficiency may also include AAT infusion therapy (with alpha-1 proteinase inhibitor, the only treatment to slow disease progression). *Brand names:* Aralasp, Glassia, Prolastin, Prolastin-C, Zemaira.

▶ *alpha-1 proteinase inhibitor (human)* (C)(G) recommended dosage of Aralast is 60 mg/kg administered once weekly via IV infusion, by a qualified healthcare provider, at a rate not to exceed 0.08 ml/kg; if any adverse event occurs, the rate should be reduced or the infusion interrupted until the symptoms subside; the infusion may then be resumed at a rate tolerated; refer to mfr pkg insert for detailed preparation directions and administration protocol.

Pediatric: safety and effectiveness in pediatric patients have not been established.

Aralast Vial: 25 ml/0.5 gm, 50 ml/1 gm (1 single-use vial of product + 1 single-use vial of diluent + 1 double-ended transfer needle and 1-20 micron filter; sterile, stable, lyophilized preparation of preservative-free purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin, for reconstitution with diluent provided; do not administer or mix with other agents or diluting solutions; when reconstituted, concentration of a1-PI is not less than 16 mg/ml and the specific activity is not less than 0.55 mg active a1-PI/mg total protein; refrigerate; do not freeze; administer within 3 hours after the reconstituted product is warmed to room temperature; discard partially used vials.

Comment: Alpha 1-Proteinase Inhibitor (Human), **Aralast**, is indicated for chronic augmentation therapy in patients having congenital deficiency of a1-PI with clinically evident emphysema. Clinical and biochemical studies have demonstrated that with such therapy, **Aralast** is effective in maintaining target serum a1-PI trough levels and increasing a1-PI levels in epithelial lining fluid (ELF). Clinical data demonstrating the long-term effects of chronic augmentation or replacement therapy of individuals with **Aralast** are not available. **Aralast** is not indicated as therapy for lung disease patients in whom congenital a1-PI deficiency has not been established. **Aralast** is contraindicated in individuals with selective IgA deficiencies (IgA level <15 mg/dl) who have known antibody against IgA, since they may experience a severe reactions, including anaphylaxis, to IgA which may be present. **Aralast** is prepared from large pools of human plasma by using the Cohn-Oncley cold alcohol fractionation process, followed by purification steps including polyethylene glycol and zinc chloride precipitations and ion exchange chromatography. To reduce the risk of viral transmission, the manufacturing process includes treatment with a solvent detergent (SD) mixture (tri-n-butyl phosphate and polysorbate 80) to inactivate enveloped viral agents, such as HIV and Hepatitis B and C. In addition, a nano-filtration step is incorporated prior to final sterile filtration to reduce the risk of transmission of non-enveloped viral agents. It is not known whether **Aralast** can cause fetal harm when administered to pregnant females or can affect reproductive capacity. It is not known whether alpha1-proteinase inhibitor is excreted in human milk.



ALZHEIMER'S DISEASE

NUTRITIONAL SUPPLEMENT

▶ *l-methylfolate calcium (as metafolin)+methylcobalamin+n-acetyl cysteine* take 1 cap once daily

Cerefolin Cap: metafo 5.6 mg+methyl 2 mg+n-ace cys 600 mg (gluten-free, yeast-free, lactose-free)

Comment: Cerefolin is indicated in the dietary management of patients treated for early memory loss, with emphasis on those at risk for neurovascular oxidative stress, hyperhomocysteinemia, mild- to- moderate cognitive impairment with or without vitamin B12 deficiency, vascular dementia, or Alzheimer's disease.

REVERSIBLE ANTICHOLINESTERASE INHIBITORS (RAIs)

Comment: The RAI drugs do not halt disease progression. They are indicated for early-stage disease; not effective for severe dementia. If treatment is stopped for more than several days, re-titrate from lowest dose. Side effects include nausea, anorexia, dyspepsia, diarrhea, headache, and dizziness. Side effects tend to resolve with continued treatment. Peak cognitive improvements are seen 12 weeks into therapy (increased spontaneity, reduced apathy, lessened confusion, and improved attention, conversational language, and performance of daily routines).

- ▶ **donepezil (C)(G)** initially 5 mg q HS, increase to 10 mg after 4-6 weeks as needed; max 23 mg/day
 - Aricept Tab:* 5, 10, 23 mg
 - Aricept ODT ODT tab:* 5, 10 mg orally-disint
- ▶ **galantamine (B)** initially 4 mg bid x at least 4 weeks; usual maintenance 8 mg bid; max 16 mg bid
 - Razadyne Tab:* 4, 8, 12 mg
 - Razadyne ER Tab:* 8, 16, 24 mg ext-rel
 - Razadyne Oral Solution Oral soln:* 4 mg/ml (100 ml w. calib pipette)
- ▶ **rivastigmine (B)(G)**
 - Exelon* initially 1.5 mg bid, increase every 2 weeks as needed; max 12 mg/day; take with food
 - Cap:* 1.5, 3, 4.5, 6 mg
 - Exelon Oral Solution* initially 1.5 mg bid; may increase by 1.5 mg bid at intervals of at least 2 weeks; usual range 6-12 mg/day; max 12 mg/day; if stopped, restart at lowest dose and re-titrate; may take directly from syringe or mix with water, fruit juice, or cola
 - Oral soln:* 2 mg/ml (120 ml w. dose syringe)
 - Exelon Patch* initially apply 4.6 mg/24 hr patch; if tolerated, may increase to 9.5 mg/24 hr patch after 4 weeks; max 13.3 mg/24 hr; change patch daily; apply to clean, dry, hairless, intact skin; rotate application site; allow 14 days before applying new patch to same site
 - Patch:* 4.6, 9.5, 13.3 mg/24 hr trans-sys (30/carton)
- ▶ **tacrine (C)** initially 10 mg qid, increase 40 mg/day q 4 weeks as needed; max 160 mg/day
 - Cognex Cap:* 10, 20, 30, 40 mg

Comment: Transaminase levels should be checked every 3 months while taking Cognex.

N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST

- ▶ **memantine (B)(G)**
 - Namenda* initially 5 mg once daily; titrate weekly in 5 mg/day increments; *Week 2:* 5 mg bid; *Week 3:* 5 mg AM and 10 mg PM; *Week 4:* 10 mg bid; *CrCl 5-29 mL/min:* max 5 mg bid
 - Tab:* 5, 10 mg
 - Namenda Oral Solution* initially 5 mg once daily; titrate weekly in 5 mg increments administered bid
 - Oral soln:* 2 mg/ml (360 ml) (peppermint) (sugar-free, alcohol-free)
 - Namenda Titration Pak*
 - Cap:* 7 x 7 mg, 7 x 14 mg, 7 x 21 mg, 7 x 28 mg/pck

Namenda XR initially 7 mg once daily; titrate in 7 mg increments weekly; max 28 mg once daily; do not divide doses

Cap: 7, 14, 21, 28 mg ext-rel

Comment: *Memantine* does not halt disease progression. It is indicated for moderate-to-severe dementia.

N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST+ ACETYLCHOLIN-ESTERASE INHIBITOR COMBINATION

- ▶ *memantine+donepezil* (C)(G) initiate one 28/10 dose daily in the evening after stabilized on *memantine* and *donepezil* separately; start the day after the last dose of *memantine* and *donepezil* taken separately; swallow whole or open cap and sprinkle on applesauce; *CrCl* 5-29 ml/min: take one 14/10 dose once daily in the evening

Namzaric

Cap: Namzaric 7/10 mem 7 mg+done 10 mg

Namzaric 14/10 mem 14 mg+done 10 mg

Namzaric 21/10 mem 21 mg+done 10 mg

Namzaric 28/10 mem 28 mg+done 10 mg

ERGOT ALKALOID (DOPAMINE AGONIST)

- ▶ *ergoloid mesylate* (C) 1 mg tid
Hydergine Tab: 1 mg
Hydergine LC Cap: 1 mg
Hydergine Liquid Liq: 1 mg/ml (100 ml w. calib dropper) (alcohol 28.5%)



AMEBIASIS

AMEBIASIS (INTESTINAL)

- ▶ *diiodohydroxyquin (iodoquinol)* (C)(G) 650 mg tid pc x 20 days
Pediatric: <6 years: 40 mg/kg/day in 3 divided doses pc x 20 days; max 1.95 gm; 6-12 years: 420 mg tid pc x 20 days
Tab: 210, 650 mg

- ▶ *metronidazole (not for use in 1st; B in 2nd, 3rd)* (G) 750 mg tid x 5-10 days
Pediatric: 35-50 mg/kg/day in 3 divided doses x 10 days
Flagyl Tab: 250*, 500*mg
Flagyl 375 Cap: 375 mg
Flagyl ER Tab: 750 mg ext-rel

- ▶ *tinidazole* (C) 2 gm daily x 3 days; take with food
Pediatric: <3 years: not recommended; ≥3 years: 50 mg/kg daily x 3 days; take with food; max 2 gm/day
Tindamax Tab: 250*, 500*mg

Comment: Other than for use in the treatment of *giardiasis* and *amebiasis* in pediatric patients older than 3 years-of-age, safety and effectiveness of *tinidazole* in pediatric patients have not been established. *tinidazole* is excreted in breast milk in concentrations similar to those seen in serum and can be detected in breast milk for up to 72 hours following administration. Interruption of breastfeeding is recommended during *tinidazole* therapy and for 3 days following the last dose.

- ▶ *paromomycin* 25-35 mg/kg/day in 3 divided doses x 5-10 days
Pediatric: same as adult
Humatin Cap: 250 mg

AMEBIASIS (EXTRA-INTESTINAL)

- ▶ *chloroquine phosphate* (C)(G) 1 gm PO daily x 2 days; then 500 mg daily x 2 to 3 weeks or 200-250 mg IM daily x 10-12 days (when oral therapy is impossible); use with intestinal amebicide

Pediatric: see mfr pkg insert

Aralen Tab: 500 mg; **Amp:** 50 mg/ml (5 ml)

AMEBIC LIVER ABSCESS

ANTI-INFECTIVES

- ▶ **metronidazole (C)(G)** 250 mg tid or 500 mg bid or 750 mg daily x 7 days

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Flagyl Tab: 250*, 500*mg

Flagyl 375 Cap: 375 mg

Flagyl ER Tab: 750 mg ext-rel

- ▶ **tinidazole (C)** 2 gm once daily x 3-5 days; take with food

Pediatric: <3 years: not recommended; ≥3 years: 50 mg/kg once daily x 3-5 days; take with food; max 2 gm/day

Tindamax Tab: 250*, 500*mg

Comment: Other than for use in the treatment of *giardiasis* and *amebiasis* in pediatric patients older than 3 years-of-age, safety and effectiveness of **tinidazole** in pediatric patients have not been established. **Tinidazole** is excreted in breast milk in concentrations similar to those seen in serum and can be detected in breast milk for up to 72 hours following administration. Interruption of breastfeeding is recommended during **tinidazole** therapy and for 3 days following the last dose.

AMENORRHEA: SECONDARY

- ▶ **estrogen+progesterone (X)**

Premarin (estrogen) 0.625 mg daily x 25 days; then 5 days off; repeat monthly

Provera (progesterone) 5-10 mg last 10 days of cycle; repeat monthly

- ▶ **estrogen replacement (X)**

see **Menopause**

- ▶ **human chorionic gonadotropin** 5,000-10,000 units IM x 1 dose following last dose of menotropins

Pregnyl Vial: 10,000 units (10 ml) w. diluent (10 ml)

- ▶ **medroxyprogesterone (X) Monthly:** 5-10 mg last 5-10 days of cycle; begin on the 16th or 21st day of cycle; repeat monthly; **One-time only:** 10 mg once daily x 10 days

Amen Tab: 10 mg

Provera Tab: 2.5, 5, 10 mg

- ▶ **norethindrone (X)** 2.5-10 mg daily x 5-10 days

Aygestin Tab: 5 mg

- ▶ **progesterone, micronized (X)(G)** 400 mg q HS x 10 days

Prometrium Cap: 100, 200 mg

Comment: Administration of **progesterone** induces optimum secretory transformation of the **estrogen**-primed endometrium. Administration of **progesterone** is contraindicated with breast cancer, undiagnosed vaginal bleeding, genital cancer, severe liver dysfunction or disease, missed abortion, thrombophlebitis, thromboembolic disorders, cerebral apoplexy, and pregnancy.

AMYOTROPHIC LATERAL SCLEROSIS (ALS, LOU GEHRIG'S DISEASE)

PYRAZOLONE FREE RADICAL SCAVENGER

- ▶ **edaravone** recommended dosage is 60 mg as an IV infusion administered over 60 minutes; Initial treatment cycle: daily dosing for 14 days, followed by a 14-day drug-free period; Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods

20 ■ Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)

Radicava IV soln: 30 mg/100 ml single-dose polypropylene bag for IV infusion (sodium bisulfite)

Comment: Most common adverse reactions (at least 10%) are confusion, gait disturbance, and headache. There are no adequate data on the developmental risk associated with the use of **Radicava** in pregnancy. There are no data on the presence of **edaravone** in human milk or the effects on the breastfed infant. However, based on animal data, may cause embryo/fetal harm.

GLUTAMATE INHIBITOR

- ▶ **riluzole** 50 mg twice daily; take at least 1 hour before or 2 hours after a meal; measure serum aminotransferases before and during treatment

Exservan Oral film: 50 mg

Comment: **Exservan (riluzole)** an oral film formulation of the approved glutamate inhibitor **riluzole** for the treatment of patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing. Use of **Exservan** is **not** recommended in patients with baseline elevations of serum aminotransferase >5 times upper limit of normal (ULN); discontinue **Exservan** if there is evidence of liver dysfunction. Monitor patient for signs and symptoms of neutropenia and advise patients to report any febrile illness. Discontinue **Exservan** if interstitial lung disease develops. Co-administration of strong-to-moderate CYP1A2 inhibitors may increase **Exservan**-associated adverse reactions. Co-administration of strong to moderate CYP1A2 inducers may result in decreased **Exservan** efficacy. **Exservan**-treated patients who take other hepatotoxic drugs may be at increased risk for hepatotoxicity. Most common adverse reactions (incidence $\geq 5\%$ and greater than placebo) have been oral hypoesthesia, asthenia, nausea, decreased lung function, hypertension, and abdominal pain. Based on animal data, **Exservan** may cause fetal harm. Decreased embryo/fetal viability, growth, and functional development was observed at clinically relevant doses. Women should be advised of a possible risk to the fetus associated with use of **Exservan** during pregnancy. There are **no** data on the presence of **riluzole** in human milk or effects on the breastfed infant. **riluzole** or its metabolites have been detected in milk of lactating animals. Developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for **Exservan** and any potential adverse effects on the breastfed infant from **Exservan** or from the underlying maternal condition.

ANAPHYLAXIS

Parenteral Corticosteroids see Appendix M. Parenteral Corticosteroids

Oral Corticosteroids see Appendix L. Oral Corticosteroids

- ▶ **epinephrine (C)(G)** 0.3-0.5 mg (0.3-0.5 ml of a 1:1000 soln) SC q 20-30 minutes as needed up to 3 doses

Pediatric: <2 years: 0.05-0.1 ml; 2-6 years: 0.1 ml; ≥ 6 -12 years: 0.2 ml; All: q 20-30 minutes as needed up to 3 doses; ≥ 12 years: same as adult

ANAPHYLAXIS EMERGENCY TREATMENT KITS

- ▶ **epinephrine (C)** 0.3 ml IM or SC in thigh; may repeat if needed
Pediatric: 0.01 mg/kg SC or IM in thigh; may repeat if needed; <15 kg: not established; 15-30 kg: 0.15 mg; >30 kg: same as adult

Adrenacllick Auto-injector: 0.15, 0.3 mg (1 mg/ml; 1, 2/carton) (sulfites)

Auvi-Q Auto-injector: 0.15, 0.3 mg (1 mg/ml; 1/pck w. 1 non-active training device) (sulfites)

EpiPen Auto-injector: 0.3 mg (epi 1:1000, 0.3 ml (1, 2/carton) (sulfites)

EpiPen Jr Auto-injector: 0.15 mg (epi 1:2000, 0.3 ml) (1, 2/carton) (sulfites)

Symjepi Prefilled Syringe: 0.3 mg (0.3 ml) single-dose for manual injection

Comment: Each **Symjepi** syringe is over-filled for stability purposes. More than half the solution remains in the syringe after use (and the syringe cannot be re-used).

Twinject Auto-injector: 0.15, 0.3 mg (epi 1:1000) (1, 2/carton) (sulfites)

- ▶ **epinephrine plus chlorpheniramine (C) epinephrine** 0.3 ml SC or IM plus 4 tabs **chlorpheniramine** by mouth

Pediatric: infants to 2 years: 0.05-0.1 ml SC or IM; ≥2-6 years: 0.15 ml SC or IM plus 1 tab chlor; ≥6-12 years: 0.2 ml SC or IM plus 2 tabs chlor; ≥12 years: same as adult

Ana-Kit: Prefilled injector: 0.3 ml epi 1:1000 for self-injection plus 4 x chlor 2 mg chew tabs



ANEMIA: BETA THALASSEMIA-ASSOCIATED

ERYTHROID MATURATION AGENT (EMA)

Comment: **Reblozyl (luspatercept-aamt)** is a first-in-class erythroid maturation agent (EMA) indicated for the treatment of beta thalassemia-associated anemia in adult patients who require regular red blood cell (RBC) transfusions. **Reblozyl** is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

- ▶ **luspatercept-aamt** recommended starting dose is 1 mg/kg SC once every 3 weeks into the upper arm, abdomen, or thigh; divide doses requiring >1.2 ml reconstituted volume into separate similar volume injections and inject into separate sites; if multiple injections are required, use a new syringe and needle for each injection; review hemoglobin (Hgb) results prior to each administration; if the patient does not achieve a reduction in RBC transfusion burden after at least 2 consecutive doses (6 weeks) at the 1 mg/kg starting dose, increase the **Reblozyl** dose to 1.25 mg/kg; do not increase the dose beyond the maximum dose of 1.25 mg/kg; if an RBC transfusion occurs prior to dosing, the pre-transfusion Hgb must be considered for dosing purposes; if a planned administration of **Reblozyl** is delayed or missed, administer **Reblozyl** as soon as possible and continue dosing as prescribed, with at least 3 weeks between doses; if the pre-dose Hgb is ≥11.5 gm/dL, and the Hgb level is not influenced by recent transfusion, delay dosing until the Hgb is ≤11 gm/dL; if the patient experiences a response followed by a lack of, or loss of, response to **Reblozyl**, initiate a search for causative factors (e.g., a bleeding event); if typical causes for a lack or loss of hematologic response are excluded, follow dosing recommendations therapy (see mfr pkg insert) for management of patients with an insufficient response to **Reblozyl**; if the patient does not experience a decrease in transfusion burden after 9 weeks of treatment (administration of 3 doses) at the maximum dose level or if unacceptable toxicity occurs at any time, **discontinue Reblozyl**

Pediatric: safety and efficacy not established

Reblozyl Vial: 25, 75 mg, single-dose; pwdr for reconstitution and SC administration (see mfr pkg insert for reconstitution directions)

Comment: There is increased risk of thrombosis/thromboembolism in patients with beta thalassemia. Monitor patients receiving **Reblozyl** for signs and symptoms of thromboembolic events and institute treatment promptly. Monitor blood pressure (BP) during treatment and initiate antihypertensive treatment if necessary. The most common adverse reactions (incidence >10%) in patients with beta thalassemia have been headache, bone pain, arthralgia, fatigue, cough, abdominal pain, diarrhea, and dizziness. There are no available

data on **Reblozyl** use in pregnant females to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, administration of *luspatercept-aamt* in pregnancy during the period of organogenesis resulted in adverse developmental outcomes, including embryo/fetal mortality, alterations to growth, and structural abnormalities at exposures (based on area under the curve [AUC]) above those occurring at the maximum recommended human dose (MRHD). Advise pregnant females of the potential embryo/fetal risk. Advise females of reproductive potential of the potential risk of embryo/fetal toxicity and to use effective contraception. Advise patient not to breastfeed. *luspatercept-aamt* has been detected in milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. There are no data on the presence of **Reblozyl** in human milk or effects on the breastfed infant. Because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with **Reblozyl** and for 3 months after the last dose.



ANEMIA OF CHRONIC KIDNEY DISEASE (CKD)/ ANEMIA OF CHRONIC RENAL FAILURE (CRF)

PHOSPHATE BINDER

- ▶ **ferric citrate** *Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis*: starting dose is 1 tablet 3 x/day with meals; adjust dose as needed to achieve and maintain hemoglobin goal, up to max 12 tabs/day; *Hyperphosphatemia in Chronic Kidney Disease on Dialysis*: starting dose is 2 tabs orally 3 x/day with meals; adjust dose by 1 to 2 tabs as needed to maintain serum phosphorus at target levels, up to max 12 tabs/day; dose can be titrated at 1 week or longer intervals
Pediatric: <18 years: not recommended; ≥18 years: same as adult

Aurexia Tab: 210 mg *ferric iron* (equivalent to 1 gm *ferric citrate*)

Comment: **Auryxia** is a phosphate binder indicated for the control of serum phosphorus levels in patients ≥18 years-of-age with chronic kidney disease (CKD) on dialysis. Ferric iron binds dietary phosphate in the GI tract and precipitates as ferric phosphate. This compound is insoluble and is excreted in the stool. **Auryxia** is also an iron replacement product indicated for the treatment of iron deficiency anemia in patients >18 years-of-age with chronic kidney (CKD) not on dialysis. Ferric iron is reduced from the ferric to the ferrous form by ferric reductase in the GI tract. After transport through the enterocytes into the blood, oxidized ferric iron circulates bound to the plasma protein transferrin, for incorporation into hemoglobin. **Auryxia** is contraindicated in iron overload syndromes (e.g., hemochromatosis). Monitor ferritin and TSAT. When clinically significant drug interactions are expected, consider separation of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medication. The most common adverse reactions (incidence ≥5%) are discolored feces, diarrhea, constipation, nausea, vomiting, cough, abdominal pain, and hyperkalemia. There are no available data on **Auryxia** use in pregnancy to inform a drug-associated risk of major birth defects and miscarriage; however, an overdose of iron may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. There are no human data regarding effects of **Auryxia** on the breastfed infant. Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years-of-age. Keep this product out of reach of children. In case of accidental overdose, contact poison control center immediately and transfer to emergency care.

ERYTHROPOIESIS STIMULATING AGENTS (ESAs)

- ▶ **darbeoetin alpha** (erythropoiesis stimulating protein) (C) administer IV or SC q 1-2 weeks; do not increase more frequently than once per month; *Not currently receiving epoetin alpha*: initially 0.75 mcg/kg once weekly; adjust based on Hgb levels (target not to exceed 12 gm/dL); reduce dose if Hgb increases more than 1 gm/dL in any 2-week period; suspend therapy if polycythemia occurs; *Converting from epoetin alpha and for dose titration*: see mfr pkg insert
Pediatric: <12 years: not recommended; ≥12 years: same as adult
Aranesp Vial: 25, 40, 60, 100, 150, 200, 300, 500 mcg/ml (single-dose) for IV or SC administration (preservative-free, albumin [human] or polysorbate 80)
Aranesp Singleject, Aranesp Sureclick Singleject Prefilled syringe: 25, 40, 60, 100, 150, 200, 300, 500 mcg (single-dose) for IV or SC administration (preservative-free, albumin [human] or polysorbate 80)
- ▶ **peginesatide** (C) use lowest effective dose; initiate when Hgb <10 gm/dL; do not increase dose more often than every 4 weeks; if Hgb rises rapidly (i.e., >1 gm/dL in 2 weeks or >2 gm/dL in 4 weeks), reduce dose by 25% or more; if Hgb approaches or exceeds 11 gm/dL, reduce or interrupt dose and then when Hgb decreases, resume dose at approximately 25% below previous dose; if Hgb does not increase by >1 gm/dL after 4 weeks, increase dose by 25%; if response is inadequate after a 12-week escalation period, use lowest dose that will maintain Hgb sufficient to reduce need for RBC transfusion; discontinue if response does not improve; *Not currently on ESA*: initially 0.04 mg/kg as a single IV or SC dose once monthly; *Converting from epoetin alfa*: administer first dose 1 week after last *epoetin alfa*; *Converting from darbeoetin alfa*: administer first dose at next scheduled dose of *darbeoetin alfa*
Pediatric: <12 years: not established; ≥12 years: use lowest effective dose
Omontys Vial, single-use: 2, 3, 4, 5, 6 mg (0.5 ml) (preservative-free); *Vial, multi-use*: 10, 20 mg (2 ml) (preservatives); *Prefilled syringe*: 2, 3, 4, 5, 6 mg (0.5 ml) (preservative-free)

ERYTHROPOIETIN HUMAN, RECOMBINANT

- ▶ **epoetin alpha** (C) individualize; initially 50-100 units/kg 3 x/week; IV (dialysis or nondialysis) or SC (nondialysis); usual max 200 units/kg 3 x/week (dialysis) or 150 units/kg 3 x/week (non-dialysis); target Hct 30-36%
Pediatric: <1 month: not recommended; ≥1 month: individualize; *Dialysis*: initially 50 units/kg 3 x/week IV or SC; target Hct 30-36%
Epogen Vial: 2,000, 3,000, 4,000, 10,000, 40,000 units/ml (1 ml) single-use for IV or SC administration (albumin [human]; preservative-free)
Epogen Multidose Vial: 10,000 units/ml (2 ml); 20,000 units/ml, (1 ml) for IV or SC administration (albumin [human]; benzoyl alcohol)
Procrit Vial: 2,000, 3,000, 4,000, 10,000, 40,000 units/ml (1 ml) single-use for IV or SC administration (albumin [human]) (preservative-free)
Procrit Multidose Vial: 10,000 units/ml (2 ml); 20,000 units/ml, (1 ml) for IV or SC administration (albumin [human]; benzoyl alcohol)
- ▶ **epoetin alfa-epbx** evaluate iron status before and during treatment and maintain iron repletion; correct or exclude other causes of anemia before initiating treatment *Patients with CKD: Initial dose (infants ≥1 month and children)*: 50 units/kg 3 x/week; *Initial dose (≥18 years-of-age)*: 50-100 units/kg 3 x/week; individualize maintenance dose; intravenous route recommended for patients on hemodialysis; *Patients on Zidovudine due to HIV-infection*: 100 units/kg 3 x/week; *Patients with Cancer on Chemotherapy*: 40,000 units once weekly or 150 units/kg 3 x weekly (adults); 600 Units/kg IV once weekly (pediatric patients >5 years); *Surgery Patients*: 300 units/kg once daily for 15 days or 600 units/kg once weekly

24 ■ Anemia of Chronic Kidney Disease (CKD)

Retacrit Vial: 2,000, 3,000, 4,000, 10,000, 40,000 units/ml (1 ml), single-dose, for SC or IV infusion

Comment: **Retacrit** (*epoetin alfa-epbx*) is the first FDA-approved biosimilar to **Epogen/Procrit** (*epoetin alfa*) for the SC or IV infusion treatment of anemia caused by chronic kidney disease (CKD), chemotherapy, or *zidovudine* treatment for human immunodeficiency virus infection. **Retacrit** is also approved for use before and after surgery to reduce the potential need for blood transfusions due to blood loss during surgery. Common reported adverse side effects with **Retacrit** include high blood pressure, joint pain, muscle spasm, fever, and dizziness. Contraindications to **Retacrit** include uncontrolled hypertension, pure red cell aplasia (PRCA) that begins after treatment with **Retacrit** or other erythropoietin protein drugs, and serious allergic reactions to **Retacrit** or other *epoetin alfa* products. BBW: ESAs increase the risk of myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence, and death (see mfr pkg insert for the full BBW). Therefore, use the lowest **Retacrit** dose sufficient to reduce the need for red blood cell (RBC) transfusions and DVT prophylaxis is recommended. The limited available data on *epoetin alfa* use in pregnancy are insufficient to determine a drug-associated risk of adverse developmental outcomes. There is no information regarding the presence of *epoetin alfa* products in human milk or effects on the breastfed infant. Safety and effectiveness in pediatric patients <1 month-of age have not been established.

ANEMIA: FOLIC ACID DEFICIENCY

- ▶ *folic acid* (A)(OTC) 0.4-1 mg once daily

Comment: *Folic acid* (*vitamin B9*) 400 mcg daily is recommended during pregnancy to prevent neural tube defects. Women who have had a baby with a neural tube defect should take 400 mcg every day, even when not planning to become pregnant, and if planning to become pregnant should take 4 mg daily during the month before becoming pregnant until at least the 12th week of pregnancy.

ANEMIA: IRON DEFICIENCY (ADA)

Comment: Hemochromatosis and hemosiderosis are contraindications to iron therapy. **Iron** supplements are best absorbed when taken between meals and with **vitamin C**-rich foods. Excessive **iron** may be extremely hazardous to infants and young children. All vitamin and mineral supplements should be kept out of the reach of children. Untreated iron deficiency anemia (IDA) in pregnancy is associated with adverse maternal outcomes such as postpartum anemia. Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight.

IRON PREPARATIONS

- ▶ *ferrous gluconate* (A)(G) 1 tab once daily

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Fergon (OTC)

Tab: iron 27 mg (240 mg as gluconate)

- ▶ *ferric maltol* 30 mg twice daily on an empty stomach (1 hour before or 2 hours after a meal); continue as long as necessary to replenish body iron stores; do not open, break, or chew

Pediatric: safety and efficacy not established

Accrufer *Cap:* 30 mg

Comment: **Accrufer** (*ferric maltol*), formerly **Feracru**, is a non-salt formulation of ferric iron for the treatment of iron deficiency in adults. **Accrufer** is **not** absorbed systemically as an intact complex following oral administration. Maternal use in pregnancy is **not** expected to result in fetal exposure and breastfeeding is **not** expected to result in exposure of the infant.

▶ **ferrous sulfate** (A)(G)

Feosol Tablets (OTC) 1 tab tid-qid pc and HS

Pediatric: <6 years: use elixir; ≥6-12 years: 1 tab tid pc

Tab: iron 65 mg (200 mg as sulfate)

Feosol Capsules (OTC) 1-2 caps daily

Pediatric: not recommended

Cap: iron 50 mg (169 mg as sulfate) sust-rel

Feosol Elixir (OTC) 5-10 ml tid between meals

Pediatric: <1 year: not recommended; >1-11 year: 2.5-5 ml tid between meals; ≥12 years: same as adult

Elix: iron 44 mg (220 mg as sulfate) per 5 ml

Fer-In-Sol (OTC) 5 ml daily

Pediatric: <4 years, use drops; ≥4 years: 5 ml once daily

Syr: iron 18 mg (90 mg as sulfate) per 5 ml (480 ml)

Fer-In-Sol Drops (OTC)

Pediatric: <4 years: 0.6 ml daily; ≥4 years: use syrup

Oral drops: iron 15 mg (75 mg as sulfate) per 5 ml (50 ml)



ANEMIA: PERNICIOUS/MEGALOBlastic

Comment: Signs of **vitamin B12** deficiency include megaloblastic anemia, glossitis, paresthesias, ataxia, spastic motor weakness, and reduced mentation.

▶ **vitamin B12** (*cyanocobalamin*) (A)(G) 500 mcg intranasally once a week; may increase dose if serum B-12 levels decline; adjust dose in 500 mcg increments

Nascobal Nasal Spray *Intranasal gel:* 500 mcg/0.1 ml (1.3 ml, 4 doses) (citric acid, benzalkonium chloride)

Comment: **Nascobal Nasal Spray** is indicated for maintenance of hematologic remission following IM B-12 therapy without nervous system involvement. Must be primed before each use.



ANESTHESIA: PROCEDURAL SEDATION

▶ **remimazolam** individualize and titrate **Byfavo** to desired clinical effect; 2.5 mg to 5 mg IV over 1-minute; if necessary, administer supplemental doses of 1.25 mg to 2.5 mg IV over 15 seconds; wait at least 2 minutes before administration of any supplemental dose; may be administered **only** by a qualified HCP who is trained in the administration of conscious sedation, who is **not** involved in the conduct of the diagnostic or therapeutic procedure, in an appropriate healthcare setting, equipped with supportive and resuscitative supplies and equipment

Pediatric: <18 years: not recommended; ≥18 years: same as adult

Byfavo *Vial:* 20 mg, single-patient, pwdr for reconstitution and intravenous push (IVP) administration

Comment: **Byfavo** (*remimazolam*) is an ultra-short-acting intravenous **benzodiazepine** sedative/anesthetic for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. The administering personnel must be trained in the detection and management of airway obstruction, hypoventilation, and apnea, including the maintenance of a patent airway, supportive ventilation, and cardiovascular resuscitation. **Byfavo** has been associated with hypoxia, bradycardia, and hypotension. Continuously monitor vital signs during sedation and through the recovery

period. Resuscitative drugs, and age- and size-appropriate equipment for bag/valve/mask-assisted ventilation must be immediately available during administration of **Byfavo**. Concomitant use of benzodiazepines with opioid analgesics may result in profound sedation, respiratory depression, coma, and death. The sedative effect of intravenous **Byfavo** can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and **propofol**. Continuously monitor patients for respiratory depression and depth of sedation. Sedating drugs, such as **Byfavo**, may cause confusion and over-sedation in the elderly; elderly patients generally should be observed closely. *Severe Hepatic Impairment*: reduced dosage may be indicated; titrate carefully to effect. Infants born to mothers using benzodiazepines during the later stages of pregnancy have been reported to experience symptoms of sedation. Although there are no data on the effects of **Byfavo** use in pregnant females, available data from published observational studies of pregnant females exposed to other benzodiazepines have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or embryo/fetal outcomes. Breastfeeding females may pump and discard breast milk for 5 hours after treatment with **Byfavo**.

ANGINA PECTORIS: STABLE

- ▶ **aspirin (D)** 325 mg (range 75-325 mg) once daily

Comment: Daily **aspirin** dose is contingent upon whether the patient is also taking an anticoagulant or antiplatelet agent.

CALCIUM ANTAGONISTS

Comment: Calcium antagonists are contraindicated with history of ventricular arrhythmias, sick sinus syndrome, 2nd or 3rd degree heart block, cardiogenic shock, acute myocardial infarction, and pulmonary congestion.

- ▶ **amlodipine (C)(G)** 5-10 mg daily

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Norvasc Tab: 2.5, 5, 10 mg

- ▶ **amlodipine benzoate** recommended starting dose 5 mg orally once daily; max 10 mg once daily; small stature, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily

Pediatric: <6 years: not studied; ≥6 years: starting dose: 2.5-5 mg once daily

Katerzia Oral susp: 1 mg/ml (150 ml), keep refrigerated

Comment: **Katerzia (amlodipine benzoate)** is a calcium channel blocker in an oral suspension formulation indicated for the treatment of hypertension in adults and children ≥6 years-of-age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. **Katerzia** is also indicated for adult patients with Coronary Artery Disease (CAD), Chronic Stable Angina (CSA), Vasospastic Angina (Prinzmetal's or Variant Angina), Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40%, at the same dose as for blood pressure management (2.5-10 mg once daily).

- ▶ **diltiazem (C)(G)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Cardizem initially 30 mg qid; may increase gradually every 1-2 days; max 360 mg/day in divided doses

Tab: 30, 60, 90, 120 mg

Cardizem CD initially 120-180 mg daily; adjust at 1- to 2-week intervals; max 480 mg/day

Cap: 120, 180, 240, 300, 360 mg ext-rel

Cardizem LA initially 180-240 mg daily; titrate at 2 week intervals; max 540 mg/day

Tab: 120, 180, 240, 300, 360, 420 mg ext-rel

Cartia XT initially 180 mg *or* 240 mg once daily; max 540 mg once daily

Cap: 120, 180, 240, 300 mg ext-rel

Dilacor XR initially 180 mg *or* 240 mg once daily; max 540 mg once daily

Cap: 180, 240 mg ext-rel

Tiazac initially 120-180 mg daily; max 540 mg/day

Cap: 120, 180, 240, 300, 360, 420 mg ext-rel

- ▼ **nicardipine (C)(G)** initially 20 mg tid; adjust q 3 days; max 120 mg/day

Pediatric: not recommended

Cardene *Cap:* 20, 30 mg

- ▼ **nifedipine (C)(G)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Adalat CC initially 30 mg once daily; usual range 30-60 mg tid; max 90 mg/day

Tab: 30, 60, 90 mg ext-rel

Procardia initially 10 mg tid; titrate over 7-14 days: max 30 mg/dose and 180 mg/day in divided doses

Cap: 10, 20 mg

Procardia XL initially 30-60 mg daily; titrate over 7-14 days; max dose 90 mg/day

Tab: 30, 60, 90 mg ext-rel

- ▼ **verapamil (C)(G)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Calan 80-120 mg tid; increase daily *or* weekly if needed

Tab: 40, 80*, 120*mg

Calan SR initially 120 mg once daily; increase weekly if needed

Tab: 120, 180, 240 mg

Covera HS initially 180 mg q HS; titrate in steps to 240 mg; then to 360 mg; then to 480 mg if needed

Tab: 180, 240 mg ext-rel

Isoptin SR initially 120-180 mg in the AM; may increase to 240 mg in the AM; then 180 mg q 12 hours *or* 240 mg in the AM and 120 mg in the PM; then 240 mg q 12 hours

Tab: 120, 180*, 240*mg sust-rel

BETA-BLOCKERS

Comment: Beta-blockers are contraindicated with history of sick sinus syndrome (SSS), 2nd *or* 3rd degree heart block, cardiogenic shock, pulmonary congestion, asthma, moderate-to-severe COPD with FEV₁ <50% predicted, patients with chronic bronchodilator treatment.

- ▼ **atenolol (D)(G)** initially 25-50 mg daily; increase weekly if needed; max 200 mg daily

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Tenormin *Tab:* 25, 50, 100 mg

- ▼ **metoprolol succinate (C)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Toprol-XL initially 100 mg in a single dose once daily; increase weekly if needed; max 400 mg/day

Tab: 25*, 50*, 100*, 200*mg ext-rel

- ▼ **metoprolol tartrate (C)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Lopressor (G) initially 25-50 mg bid; increase weekly if needed; max 400 mg/day

Tab: 25, 37.5, 50, 75, 100 mg

28 ■ Angina Pectoris: Stable

- ▶ **nadolol (C)(G)** initially 40 mg daily; increase q 3-7 days; max 240 mg/day

Pediatric: not recommended

Corgard Tab: 20*, 40*, 80*, 120*, 160*mg

- ▶ **propranolol (C)(G)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Inderal LA initially 80 mg daily in a single dose; increase q 3-7 days; usual range 120-160 mg/day; max 320 mg/day in a single dose

Cap: 60, 80, 120, 160 mg sust-rel

InnoPran XL initially 80 mg q HS; max 120 mg/day

Cap: 80, 120 mg ext-rel

NITRATES

Comment: Use a daily nitrate dosing schedule that provides a dose-free period of 14 hours or more to prevent tolerance. *aspirin* and *acetaminophen* may relieve nitrate-induced headache. *Isosorbide* is not recommended for use in MI and/or CHF. Nitrate use is a contraindication for using phosphodiesterase type 5 inhibitors: *sildenafil (Viagra)*, *tadalafil (Cialis)*, *varidenafil (Levitra)*.

- ▶ **isosorbide dinitrate (C)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Dilatrate-SR 40 mg once daily; max 160 mg/day

Cap: 40 mg sust-rel

Isordil Titradose initially 5-20 mg q 6 hours; maintenance 10-40 mg q 6 hours

Tab: 5, 10, 20, 30, 40 mg

- ▶ **isosorbide mononitrate (C)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Imdur initially 30-60 mg q AM; may increase to 120 mg daily; max 240 mg/day

Tab: 30*, 60*, 120 mg ext-rel

Ismo 20 mg upon awakening; then 20 mg 7 hours later

Tab: 20*mg

- ▶ **nitroglycerin (C)(G)**

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Nitro-Bid Ointment initially 1/2 inch q 8 hours; titrate in 1/2 inch increments

Oint: 2% (20, 60 gm)

Nitrodisc initially one 0.2-0.4 mg/Hr patch for 12-14 hours/day

Transdermal disc: 0.2, 0.3, 0.4 mg/hour (30, 100/carton)

Nitrolingual Pump Spray 1-2 sprays on or under tongue; max 3 sprays/15 minutes

Spray: 0.4 mg/dose (14.5 gm, 200 doses)

Nitromist 1-2 sprays at onset of attack, on or under the tongue while sitting; may repeat q 5 minutes as needed; max 3 sprays/15 minutes; may use prophylactically 5-10 minutes prior to exertion; do not inhale spray; do not rinse mouth for 5-10 minutes after use

Lingual aerosol spray: 0.4 mg/actuation (230 metered sprays)

Nitrostat 1 tab SL; may repeat q 5 minutes x 3

SL tab: 0.3 (1/100 gr), 0.4 (1/150 gr), 0.6 (1/4 gr) mg

Transderm-Nitro initially one 0.2 mg/hour or 0.4 mg/hour patch for 12-14 hours/day

Transdermal patch: 0.1, 0.2, 0.4, 0.6, 0.8 mg/hour

NON-NITRATE PERIPHERAL VASODILATOR

- ▶ **hydralazine (C)(G)** initially 10 mg qid x 2-4 days; then increase to 25 mg qid for remainder of first week; then increase to 50 mg qid; max 300 mg/day

Pediatric: <12 years: not recommended; ≥12 years: same as adult

Tab: 10, 25, 50, 100 mg